A three-dimensional human neural cell culture model of Alzheimer's disease.
paper
Cited
Public
- Authors
- Choi, Se Hoon; Kim, Young Hye; Hebisch, Matthias; Sliwinski, Christopher; Lee, Seungkyu; D'Avanzo, Carla; Chen, Hechao; Hooli, Basavaraj; Asselin, Caroline; Muffat, Julien; Klee, Justin B; Zhang, Can; Wainger, Brian J; Peitz, Michael; Kovacs, Dora M; Woolf, Clifford J; Wagner, Steven L; Tanzi, Rudolph E; Kim, Doo Yeon
- Year
- 2014
- Journal
- Nature
- PMID
- 25307057
- DOI
- 10.1038/nature13800
- PMCID
- PMC4366007
Alzheimer's disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-β plaques and neurofibrillary tangles. The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-β peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau. However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-β-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology. Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-β species and phosphorylated tau but did not demonstrate amyloid-β plaques or neurofibrillary tangles. Here we report that FAD mutations in β-amyloid precursor protein and presenilin 1 are able to induce robust extracellular deposition of amyloid-β, including amyloid-β plaques, in a human neural stem-cell-derived three-dimensional (3D) culture system. More importantly, the 3D-differentiated neuronal cells expressing FAD mutations exhibited high levels of detergent-resistant, silver-positive aggregates of phosphorylated tau in the soma and neurites, as well as filamentous tau, as detected by immunoelectron microscopy. Inhibition of amyloid-β generation with β- or γ-secretase inhibitors not only decreased amyloid-β pathology, but also attenuated tauopathy. We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-β-mediated tau phosphorylation. We have successfully recapitulated amyloid-β and tau pathology in a single 3D human neural cell culture system. Our unique strategy for recapitulating Alzheimer's disease pathology in a 3D neural cell culture model should also serve to facilitate the development of more precise human neural cell models of other neurodegenerative disorders.
Generation of hNPCs with multiple FAD mutationsa. Diagrams showing lentiviral IRES constructs. APPSL, APP with Swedish/London mutations; PS1ΔE9, PS1 with ΔE9 mutation; GFP, eGFP. b. Increased Aβ40 and 42 levels in 6-week differentiated FAD ReN cells. Aβ levels in conditioned media were normalized to total protein levels (*, p<0.05; **, p<0.01; ***, p<0.001; ANOVA followed by a post-hoc Dunnett test; n=3 per each sample). c. Aβ levels are dramatically decreased in FAD ReN cells after treatment with 1 μM BACE1 inhibitor IV or 3.7 nM Compound E (mean ± s.e.m; *, p<0.05; **, p<0.01; ***, p<0.001; ANOVA followed by a post-hoc Dunnett test; n=3 per each sample; n.d. not detected).
FACS enrichment of ReN-mAP and ReN-m cells for higher expressions of APP and PS1a. FACS sorting of ReN-mAP cells with top 1–2% mCherry signal. b. The enriched control ReN-m and ReN-mAP cells were differentiated by growth-factor deprivation in 2D cultures. c. The enriched ReN-mAP cells secreted high levels of Aβ40 and 42 after 9-week 3D differentiation. The secreted Aβ38/40/42 levels were measured by a multi-array Meso Scale electrochemiluminescence (Meso Scale SQ 120 system). Relative levels of Aβ (fold increases) were calculated by setting Aβ levels of the control ReN-m as 1. Aβ levels were decreased after treating 1 μM BACE1 inhibitor IV, 3.7 nM Compound E or 500 nM SGSM41 (**, p<0.01; ***, p<0.001; ANOVA followed by a post-hoc Dunnett’s test; n=3 for the enriched ReN-m and -mAP, respectively).
Increased p-tau levels in FAD ReN cellsa. IF of AT8 p-tau and MAP2 in the enriched ReN-mAP and control ReN-m cells after 9 weeks of 3D-differentiation. A BACE1 inhibitor (BACE1 inhibitor IV) treatment for 3 weeks, dramatically reduced AT8 p-tau staining (green, AT8 p-tau; red (pseudo-colored), MAP2; scale bar, 25 μm). b. WB of total and p-tau levels in control (ReN-m) and FAD ReN (enriched ReN-mAP) cells. The cells were 3D-differentiated for 9 weeks. 3 weeks of BACE1 inhibitor treatments significantly decreased p-tau levels without changing total tau levels. HSP70 heat shock protein levels were shown for equal loadings of each sample.
Immuno-EM analysis of sarkosyl-insoluble fraction from FAD and control ReN cellsa. Sarkosyl-insoluble fractions prepared from 3D-differentiated ReN-mAP (enriched, 7-week differentiated), were placed on carbon grids, labeled with tau46 and anti-mouse 10 nm gold antibodies and imaged by using a JEOL JEM 1011 transmission electron microscope (Scale bar, 500 nm). b. Sarkosyl-insoluble fractions from 3D-differentiated control ReN-G cells (7 weeks). No immunogold-labeled filamentous structures were detected in these samples (Scale bar, 500 nm).
1-Azakenpaullone, a GSK3 inhibitor treatment decreased Aβ-induced tau phosphorylation without changing the total Aβ levelsa. IF of p-tau and MAP2 in the enriched ReN-mAP and control ReN-m cells with or without treating 1-Azakenpaullone, a GSK3β inhibitor. The differentiated cells were treated with 2.5 μM 1-Azakenpaullone (GSK3β inhibitor) or DMSO for the last 5 days of the 3D differentiation (green, p-tau (PHF1); red (pseudo-colored), MAP2; scale bar, 25 μm). b. WB of total and p-tau levels in control (ReN-m) and FAD ReN (enriched ReN-mAP) cells. The cells were 3D-differentiated for 4 weeks followed by additional 5-day treatments of DMSO or 2.5 μM 1-Azakenpaullone. c. Analysis of Aβ40 and 42 levels in the enriched ReN-mAP cells treated with either DMSO or 2.5 μM 1-Azakenpaullone (1-Aza) under the same conditions.
Robust increases of extracellular Aβ deposits in 3D-differentiated hNPCs with FAD mutationsa. Thin layer 3D culture protocols (IF, immunofluorescence; HC, histochemical; IHC, immunohistochemical staining). b. Aβ deposits in 6-week differentiated control and FAD ReN cells in 3D Matrigel (green, GFP; blue, 3D6; scale bar, 25 μm; arrowheads, extracellular Aβ deposits; right-most panels, 3D6 staining was pseudo-colored to red). c. Select confocal z-stack images of 3D6-positive Aβ deposits. Z-sections with an interval of 2 μm were captured and the sections #1,3–4, #6 and #19 are shown (green, GFP; red, 3D6). d. IHC of Aβ deposits in ReN-mGAP cells. 3D-differentiated cells were treated with 1 μM BACE inhibitor IV, 500 nM DAPT, 500 nM SGSM41 or DMSO (brown, DAB (BA27); blue, hematoxylin; scale bar, 25 μm; arrowheads, large Aβ deposits). e. Detection of amyloid plaques with Amylo-Glo, a fluorescent amyloid-specific dye (Green, GFP; blue, Amylo-Glo; arrows, Amylo-Glo positive aggregates).
Elevation of Aβ and p-tau levels in TBS-insoluble fractions of 3D-differentiated FAD hNPCsa. A diagram showing a thick-layer 3D culture and detergent extraction protocols. b. WB of Aβ aggregates in 3D-differentiated ReN cells. 6E10 antibody detected Aβ monomers, dimers, trimers and tetramers in SDS-soluble (upper panel) and formic acid-soluble fractions (lower panel) from the control (ReN-G and -m) and the FAD ReN cells (ReN-GA, ReN-mGAP and HReN-mGAP) after 6-week differentiation. c. WB of total and p-tau levels in SDS-soluble and formic acid-soluble fractions.
Detection of aggregated p-tau in the enriched ReN-mAP cellsa. IF of p-tau and MAP2 in the enriched ReN-mAP and ReN-m cells after 3D differentiation (green, p-tau (PHF1); red (pseudo-colored), MAP2; scale bar, 25 μm; arrows, p-tau positive neurites; arrowheads, p-tau positive cell bodies). b. IHC of p-tau in the enriched ReN-mAP and ReN-m cells after 10-week 3D differentiation. The cells were treated with 1 μM BACE1 Inhibitor IV, 3.7 nM compound E or DMSO for the final two weeks of the 3D differentiation. PHF1 antibody detected the elevated levels of p-tau in soma and neurites (brown, p-tau; scale bar, 25 μm). c. WB of total and p-tau levels in 1% sarkosyl-soluble and -insoluble fractions. d. The modified Gallyas silver staining showed robust increases of strong silver deposits in cell bodies and neurite-like structures in the enriched ReN-mAP cells (lower panel) but not in ReN-m cells (upper panel; scale bar, 25 μm). e. Tau filaments were detected in sarkosyl-insoluble fractions from the enriched ReN-mAP cells by transmission electron microscopy (7-week 3D differentiation; black dots, anti-tau (tau46) antibodies labeled with immunogold anti-mouse antibodies; scale bar, 100 nm). Lower panel: an enlarged image (arrowheads indicate filamentous structures).
Generation of FACS-sorted ReN cells with FAD mutationsa. FACS sorting of ReNcell VM human neural stem (ReN) cells that were stably transfected with polycistronic GFP and/or mCherry lentiviral Vector. The cells were then enriched based on GFP and/or mCherry signals by FACS (red-dotted boxes, the selected ranges of cells for the experiments). b. ReN cells stably expressing GFP alone (ReN-G), APPSL/GFP (ReN-GA), APPSL/GFP/PS1ΔE9/mCherry (ReN-mGAP), mCherry alone (ReN-m), APPSL/PS1ΔE9/mCherry (ReN-mAP) or GFP/APPSL/PS1ΔE9/mCherry (HReN-mGAP). Green, GFP; Red, mCherry; Scale bar, 25 μm. c. The representative fluorescence microscope images of ReN cells that were differentiated by growth-factor deprivation for 3 weeks (green, GFP; red, mCherry; scale bar, 25 μm). d. IF of neuronal (Tuj-1, blue) and glial markers (GFAP, blue) in 3-week differentiated control and FAD ReN cells. e. WB of APPSL and PS1ΔE9 expression in control (ReN-G and ReN-m) and FAD ReN (ReN-GA, ReN-mGAP and HReN-mGAP) cells. APP C-terminal fragments levels were largely increased by 500 nM DAPT treatments for 24 hours. f. A table summarizing the control and FAD ReN cells generated for this study.
Characterization of the control and FAD ReN cellsa. WB of neuronal (MAP2, Tuj1, NCAM, Synapsin 1) and glial (GFAP) markers in undifferentiated and 3-week differentiated control and FAD ReN cells. b. Confocal IF of presynaptic (VGluT1, green) and dendritic (MAP2, red (pseudo-colored)) markers in 6-week differentiated control ReN-m cells. c. qPCR array analysis of neuronal and glial markers of 7-week differentiated control ReN-G cells. Gene expression levels were normalized against β-actin levels in each sample and the fold changes were calculated by setting the expression levels of each genes in undifferentiated control ReN-G cells as 1 (n=3 for ReN-G while n=5 for ReN-G in 3D-differentiatiation). FAD (HReN-mGAP and ReN-mAP) ReN cells showed a similar pattern of increases in neuronal and glial markers (data not shown). d. Analysis of 4-repeat (4R) or 3-repeat (3R) tau isoforms in 7-week differentiated control (ReN-G and ReN-m) and FAD (ReN-GA, ReN-mGAP, HReN-mGAP and ReN-mAP) ReN cells. cDNA samples prepared from undifferentiated control ReN-G (1st lane) and human adult brains (9th lane) were used as controls. e and f. Electrophysiological properties of differentiated control ReN-G cells. The currents were elicited by 10 mV voltage steps from -100 to +60 mV in external solution (e) without (left panel in f) or with 500 nM tetrodotoxin (TTX, right panel in f). TTX treatment specifically blocked voltage-gated sodium currents. ReN-G cells were differentiated for 29 days by the “preD” method as previously described12. g. Sodium currents are shown as subtracted currents. h. Premature ReN-G (<16 days) cells mostly showed voltage-gated potassium currents without TTX-sensitive sodium currents. i. WB of Aβ levels in the conditioned media collected from 6-week differentiated control (ReN-m) and FAD ReN (ReN-mAP and HReN-mGAP) cells. j. A table summarizing APOE genotypes of control (ReN-m) and FAD ReN (ReN-mAP) cells used in this study. Two APOE SNP markers rs429358 (minor allele=C) and rs7412 (minor allele=T) were used to determine APOE2/3/4 genotypes.
Characterization of differentiated ReN cells in 3D culturesa. Hematoxylin staining of a representative paraffin section (10 μm) from 9-week differentiated ReN-m cells in thick layer 3D Matrigel. The sections were vertically cut to show the top and bottom of the 3D cultures. The digital pictures were serially taken from top to bottom and combined together (bottom panel: an enlarged picture). b. The paraffin sections from control (ReN-G and ReN-m) and FAD ReN (ReN-GA and ReN-mAP (enriched)) were IF stained with the following antibodies against neuronal markers, Tuj1 and MAP2. Blue, DAPI; scale bar, 25 μm. c. IF of thick layer 3D-differentiated ReN-m cells with the following antibodies against additional neuronal markers. Green, tau, VGluT1 (Vesicular glutamate transporter 1), or GluR2 (Glutamate Receptor, Ionotropic, AMPA 2); scale bar, 25 μm. d. IF of 3D-differentiated ReN-m cells (7 weeks) with the antibodies against mature neuronal markers. Green, TH (tyrosine hydroxylase), NR2B (NMDA receptor 2B) or GABA(B)R2 (GABB-B-receptor 2); Blue, DAPI; scale bar, 20 μm.
Reconstitution of Aβ aggregates in 3D-cultured FAD ReN cellsa. IHC of Aβ deposits in control (ReN-G) and FAD ReN (HReN-mGAP) cells differentiated in 3D Matrigel. The control and FAD ReN cells were 3D-differentiated for 6 weeks and then treated with 1 μM BACE1 inhibitor IV (β-secretase inhibitor), 500 nM DAPT (γ-secretase inhibitor), 500 nM SGSM41 (γ-secretase modulator) or DMSO for additional 3 weeks. The cultures were then fixed and immunostained with HRP-conjugated BA27 anti-Aβ40 antibodies (brown, DAB (BA27); blue, hematoxylin; scale bar, 25 μm; arrowheads, large Aβ deposits). b. The enlarged images of Aβ deposits in control (ReN-G) and FAD ReN (ReN-mGAP, HReN-mGAP) cell pictures shown in Fig. 2d and Extended Data Fig. 4a). c. IHC of Aβ deposits in control (ReN-G, left panels) and FAD ReN (ReN-mGAP: middle panels; HReN-mGAP: right panels) cells differentiated in 3D thin layer Matrigels for 9 weeks. The fixed thin-layer 3D cultures were immunostained with HRP-conjugated BA27 anti-Aβ40 antibodies (brown, DAB (BA27); scale bar, 25 mm; arrows, large Aβ deposits). d. Amylo-Glo staining of ReN-G 3D cultures. Green, GFP; Blue, Amylo-Glo.
Accumulation of p-tau in FAD ReN cellsa. Elevated p-tau levels were significantly decreased by 1 μM DAPT (γ-secretase inhibitor) treatment in 6-week differentiated HReN-mGAP cells. The antibody against human specific mitochondrial marker (h-mito) was used to show an equal loading of the samples. b. Quantitation of p-tau levels in control and DAPT-treated HReN-mGAP cells (**, p<0.01; t-test; n=3 per each sample). c. p-tau IHC showed p-tau positive cells in 3D-differentiated FAD ReN cells. Two p-tau antibodies, AT8 (pSer199/Ser202/Thr205) and PHF1 (pSer396/Ser404), against different phosphorylation sites were used. Brown, p-tau; Scale bar, 25 μm; arrows indicate the cells with high levels of p-tau. d. High magnification (1,000x) images of p-tau positive neurons (brown, AT8 p-tau). IHC of AT8 p-tau staining showed neurons with high levels of p-tau accumulation in soma and neurite-like structures (arrowheads). e. IHC of p-tau (AT8) staining showed the cells with p-tau accumulations in soma and neurite-like structures (arrow and arrowheads). f. An enlarged image of a dotted box in e (brown: p-tau (AT8); blue: hematoxylin). g. Total number of cells with high levels of p-tau in single 96-well was counted in control (ReN-G and ReN-m) and FAD ReN (ReN-GA, ReN-mGAP and HReN-mGAP) cells (*, p<0.05; t-test; n=5 for control ReN cells and 12 for FAD ReN cells). h. BACE inhibitor IV (1 μM) or Compound E (3.7 nM) treatments largely decreased cells with high p-tau accumulation in ReN-mAP cells (***, p<0.001; ANOVA followed by a post-hoc Dunnett’s test; n=3 for control ReN-m and ReN-mAP cells).
← Prev
21–30 of 30
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Central integration mechanisms of neurovascular unit dysfunction and novel synergistic therapeutic strategies. | Wang H et al. | — | 2026 | → |
| Deep Profiling of the Aging Proteome Depicts Neuroinflammation, Synaptic Function, and Phosphorylation in an Accelerated Alzheimer's Disease Cell Model. | Gentry E et al. | — | 2026 | → |
| Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease. | Niziński P et al. | — | 2026 | → |
| Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine. | Lee CJ et al. | — | 2026 | → |
| Human in vitro and rodent in vivo models highlight progressive mitochondrial dysfunction as a starting point of cerebral amyloidosis. | Motamed Z et al. | — | 2026 | → |
| Intracellular protein GBF1 displays significant associations with amyloid pathology in Alzheimer's disease. | Miller SJ et al. | — | 2026 | → |
| <i>RIN3</i> mutations impairing binding of the Alzheimer's disease-associated protein BIN1 lead to RAB5 hyperactivation and endosomal pathology. | Maaser-Hecker AK et al. | — | 2026 | → |
| Multi-omic analysis of guided and unguided forebrain organoids reveals differences in cellular composition and metabolic profiles. | Øhlenschlæger MS et al. | — | 2026 | → |
| Neuronal Organoid Engineering and Disease-Focused High-Throughput Neuropharmacology: Advances, Limitations, and Translational Strategies. | Farasati Far B et al. | — | 2026 | → |
| Phosphorylated tau exhibits antimicrobial activity capable of neutralizing herpes simplex virus 1 infectivity in human neurons. | Eimer WA et al. | — | 2026 | → |
| Proteomic profiling of brain organoids and extracellular vesicles identifies early Alzheimer's disease biomarkers and drug response heterogeneity. | Boyd RJ et al. | — | 2026 | → |
| Recapitulation of plaque formation, tau pathology, and neurodegeneration in a human 3D matrix model of Alzheimer's disease. | Hebisch M et al. | — | 2026 | → |
| The rise and deceleration of neuronal excitability in aging and Alzheimer's disease: Mechanisms, implications, and therapeutic targets. | Delbono O et al. | — | 2026 | → |
| TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathology. | König LE et al. | — | 2026 | → |
| A 3D human iPSC-derived multi-cell type neurosphere system to model cellular responses to chronic amyloidosis. | Wendt S et al. | — | 2025 | → |
| Advancement in modeling of Alzheimer's disease: a comprehensive review of preclinical screening platforms. | Adak S et al. | — | 2025 | → |
| Age-Related Neurodegenerative Diseases: A Stem Cell's Perspective. | Calvo B et al. | — | 2025 | → |
| Alzheimer's disease patient brain extracts induce multiple pathologies in novel vascularized neuroimmune organoids for disease modeling and drug discovery. | Ji Y et al. | — | 2025 | → |
| Alzheimer's Is a Multiform Disease of Sustained Neuronal Integrated Stress Response Driven by the C99 Fragment Generated Independently of AβPP; Proteolytic Production of Aβ Is Suppressed in AD-Affected Neurons: Evolution of a Theory. | Volloch V et al. | — | 2025 | → |
| Amyloid-β Seeds in Alzheimer's Disease: Research Challenges and Implications. | Beschorner N et al. | — | 2025 | → |
| A neuroimmune cerebral assembloid model to study the pathophysiology of familial Alzheimer's disease. | Becerra-Calixto A et al. | — | 2025 | → |
| A new protocol for the development of organoids based on molecular mechanisms in the developing newborn rat brain: Prospective applications in the study of Alzheimer's disease. | Tzekaki E et al. | — | 2025 | → |
| An optimized method for directed differentiation of hypothalamic neural stem cells in a 3D culture system. | Luo J et al. | — | 2025 | → |
| Beyond Transgenic Mice: Emerging Models and Translational Strategies in Alzheimer's Disease. | Alexandra Lopes P et al. | — | 2025 | → |
| Brain organoids: building higher-order complexity and neural circuitry models. | Maisumu G et al. | — | 2025 | → |
| Chemical Tomography of Cancer Organoids and Cyto-Proteo-Genomic Development Stages Through Chemical Communication Signals. | Maity A et al. | — | 2025 | → |
| Cryopreserving 3D cell culture models of Alzheimer's disease in hydrogel microbeads. | Kim JJ et al. | — | 2025 | → |
| Current Development of iPSC-Based Modeling in Neurodegenerative Diseases. | Guo X et al. | — | 2025 | → |
| Emerging Insights into Brain Inflammation: Stem-Cell-Based Approaches for Regenerative Medicine. | Karam M et al. | — | 2025 | → |
| Engineered 3D human neurovascular model of Alzheimer's disease to study vascular dysfunction. | Pavlou G et al. | — | 2025 | → |
| Engineered 3D immuno-glial-neurovascular human miBrain model. | Stanton AE et al. | — | 2025 | → |
| Establishment and characterization of Cri Du Chat neuronal stem cells: a novel promising resource to study the syndrome. | Piovani G et al. | — | 2025 | → |
| Establishment of a Depression Model Using Dexamethasone-treated Three-dimensional Cultured Rat Cortical Cells. | Seo MK et al. | — | 2025 | → |
| Formaldehyde induces and promotes Alzheimer's disease pathologies in a 3D human neural cell culture model. | Wu P et al. | — | 2025 | → |
| Human amylin is a potent antimicrobial peptide that exhibits antimicrobial synergism with the amyloid beta protein. | Vijaya Kumar DK et al. | — | 2025 | → |
| Human and mouse proteomics reveals the shared pathways in Alzheimer's disease and delayed protein turnover in the amyloidome. | Yarbro JM et al. | — | 2025 | → |
| Human brain organoids: an innovative model for neurological disorder research and therapy. | Li H et al. | — | 2025 | → |
| Hypotonic Swelling Method for the Isolation of Pure Mitochondria From Primary Human Skeletal Myoblasts for Proteomic Studies. | Aksu-Menges E et al. | — | 2025 | → |
| Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy. | Bagherpour I et al. | — | 2025 | → |
| Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer's disease. | Naderi Yeganeh P et al. | — | 2025 | → |
| Laminin-Functionalized Gelatin Microgels for the Generation of Functional Neurons from Neural Progenitor Cells. | Edwards SD et al. | — | 2025 | → |
| Locus coeruleus tau is linked to successive cortical tau accumulation. | Yi D et al. | — | 2025 | → |
| Magnetic Levitational Assembly of Differentiated SH-SY5Y Cells for Aβ-Induced 3D Alzheimer's Disease Modeling and Curcumin Screening. | Bilginer-Kartal R et al. | — | 2025 | → |
| Mapping amyloid beta predictors of entorhinal tau in preclinical Alzheimer's disease. | Zamani J et al. | — | 2025 | → |
| Microglia depletion reduces human neuronal APOE4-related pathologies in a chimeric Alzheimer's disease model. | Rao A et al. | — | 2025 | → |
| Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States. | Kuhn MK et al. | — | 2025 | → |
| Modeling Alzheimer's Disease: A Review of Gene-Modified and Induced Animal Models, Complex Cell Culture Models, and Computational Modeling. | Timofeeva AM et al. | — | 2025 | → |
| Modeling neurodegenerative diseases with brain organoids: from development to disease applications. | Larriba-González T et al. | — | 2025 | → |
| Modeling Sporadic Progressive Supranuclear Palsy in 3D Midbrain Organoids: Recapitulating Disease Features for In Vitro Diagnosis and Drug Discovery. | Parrotta EI et al. | — | 2025 | → |
| NEAT1-mediated regulation of proteostasis and mRNA localization impacts autophagy dysregulation in Rett syndrome. | Siqueira E et al. | — | 2025 | → |
| Neurobiological Perturbations in Bipolar Disorder Compared With Schizophrenia: Evidence From Cell Cultures and Brain Organoids. | Akkouh IA et al. | — | 2025 | → |
| Neuroinflammation Based Neurodegenerative In Vitro Model of SH-SY5Y Cells-Differential Effects on Oxidative Stress and Insulin Resistance Relevant to Alzheimer's Pathology. | Böröczky C et al. | — | 2025 | → |
| One-Step Drug Screening System Utilizing Electrophysiological Activity in Multiple Brain Organoids. | Shin H et al. | — | 2025 | → |
| Potential Applications of Natural Components of Traditional Chinese Medicine Delivery via Nanoparticle Drug Delivery Systems in the Treatment of Alzheimer's Disease. | Lai G et al. | — | 2025 | → |
| Production of Amyloid-β in the Aβ-Protein-Precursor Proteolytic Pathway Is Discontinued or Severely Suppressed in Alzheimer's Disease-Affected Neurons: Contesting the 'Obvious'. | Volloch V et al. | — | 2025 | → |
| Regulatory role of LncRNA FMR1-AS1 in the pathogenesis of alzheimer's disease based on bioinformatics and in vitro experimental validation. | Yu X et al. | — | 2025 | → |
| Relationship between exosomes and cancer: formation, diagnosis, and treatment. | Huang C et al. | — | 2025 | → |
| Research models to study lewy body dementia. | Boschen SL et al. | — | 2025 | → |
| Research Progress on Neural Cell Culture Systems. | Li T et al. | — | 2025 | → |
| Senolytics rejuvenate aging cardiomyopathy in human cardiac organoids. | Scalise M et al. | — | 2025 | → |
| Stabilization of mitochondria-associated endoplasmic reticulum membranes regulates Aβ generation in a three-dimensional neural model of Alzheimer's disease. | Zellmer JC et al. | — | 2025 | → |
| Stem cell-based therapeutic strategies for down syndrome and Alzheimer's disease. | Hamadelseed O et al. | — | 2025 | → |
| Systematic analysis of cellular cross-talk reveals a role for SEMA6D-TREM2 regulating microglial function in Alzheimer's disease. | D'Oliveira Albanus R et al. | — | 2025 | → |
| Tau aggregation induces cell death in iPSC-derived neurons. | Tanabe H et al. | — | 2025 | → |
| The potential of carbohydrate supramolecular hydrogels for long-term 3D culture of primary fibroblasts. | Kasmi N et al. | — | 2025 | → |
| Therapeutic potential of exercise-hormone irisin in Alzheimer's disease. | Kim E et al. | — | 2025 | → |
| Tissue-Engineered Three-Dimensional Platforms for Disease Modeling and Therapeutic Development. | Wheeler EE et al. | — | 2025 | → |
| Transforming surgical planning and procedures through the synergistic use of additive manufacturing, advanced materials and artificial intelligence: challenges and opportunities. | Tripathi S et al. | — | 2025 | → |
| Two- and Three-Dimensional In Vitro Models of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Applications. | Solana-Manrique C et al. | — | 2025 | → |
| Unveiling roles of NGLY1 in cellular homeostasis and related diseases. | Zhan C et al. | — | 2025 | → |
| 3D bioprinting of human neural tissues with functional connectivity. | Yan Y et al. | — | 2024 | → |
| ACH2.0/E, the Consolidated Theory of Conventional and Unconventional Alzheimer's Disease: Origins, Progression, and Therapeutic Strategies. | Volloch V et al. | — | 2024 | → |
| Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer's disease. | Cuní-López C et al. | — | 2024 | → |
| A framework for translating tauopathy therapeutics: Drug discovery to clinical trials. | Feldman HH et al. | — | 2024 | → |
| Aging phenotype in AD brain organoids: Track to success and challenges. | Hossain MK et al. | — | 2024 | → |
| Alzheimer's Disease from Modeling to Mechanism Research. | Sun X et al. | — | 2024 | → |
| Animal models in neuroscience with alternative approaches: Evolutionary, biomedical, and ethical perspectives. | Neziri S et al. | — | 2024 | → |
| Approaches for studying neuroimmune interactions in Alzheimer's disease. | Lin C' et al. | — | 2024 | → |
| Assessment of the level of apoptosis in differentiated pseudo-neuronal cells derived from neural stem cells under the influence of various inducers. | Naghshbandieh A et al. | — | 2024 | → |
| Brain Microvascular Pericyte Pathology Linking Alzheimer's Disease to Diabetes. | El-Ghazawi K et al. | — | 2024 | → |
| Brain organoids: A revolutionary tool for modeling neurological disorders and development of therapeutics. | Acharya P et al. | — | 2024 | → |
| Cellular reprogramming as a tool to model human aging in a dish. | Pitrez PR et al. | — | 2024 | → |
| Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease. | Xia Z et al. | — | 2024 | → |
| Disrupted mitochondrial response to nutrients is a presymptomatic event in the cortex of the APP<sup>SAA</sup> knock-in mouse model of Alzheimer's disease. | Norambuena A et al. | — | 2024 | → |
| Effects of Aerobic Exercise on Brain Age and Health in Middle-Aged and Older Adults: A Single-Arm Pilot Clinical Trial. | Ouyang A et al. | — | 2024 | → |
| Engineering 3D Scaffold-Free Nanoparticle-Laden Stem Cell Constructs for Piezoelectric Enhancement of Human Neural Tissue Formation and Function. | James EC et al. | — | 2024 | → |
| FGFR3 drives Aβ-induced tau uptake. | Kim DK et al. | — | 2024 | → |
| Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies. | Langerscheidt F et al. | — | 2024 | → |
| Geometrically engineered organoid units and their assembly for pre-construction of organ structures. | Kadotani A et al. | — | 2024 | → |
| High-Throughput Assessment of Metabolism-Mediated Neurotoxicity by Co-Culture of Neurospheres and Liver Spheroids. | Joshi P et al. | — | 2024 | → |
| Human stem cell transplantation models of Alzheimer's disease. | Ifediora N et al. | — | 2024 | → |
| In and out: Benchmarking in vitro, in vivo, ex vivo, and xenografting approaches for an integrative brain disease modeling pipeline. | Pereira MF et al. | — | 2024 | → |
| Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia. | McInvale JJ et al. | — | 2024 | → |
| Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling. | Beghini DG et al. | — | 2024 | → |
| Intracellular tau fragment droplets serve as seeds for tau fibrils. | Soeda Y et al. | — | 2024 | → |
| Irisin limits amyloid-β buildup in Alzheimer's disease. | Lourenco MV | — | 2024 | → |
| Leveraging Biomaterial Platforms to Study Aging-Related Neural and Muscular Degeneration. | Hidalgo-Alvarez V et al. | — | 2024 | → |
| Live-cell visualization of tau aggregation in human neurons. | Hurtle B et al. | — | 2024 | → |
| Microphysiological systems for human aging research. | Park S et al. | — | 2024 | → |
| Modeling Alzheimer's disease using human cell derived brain organoids and 3D models. | Fernandes S et al. | — | 2024 | → |
| Modeling late-onset Alzheimer's disease neuropathology via direct neuronal reprogramming. | Sun Z et al. | — | 2024 | → |
| Neuron(s)-on-a-Chip: A Review of the Design and Use of Microfluidic Systems for Neural Tissue Culture. | Buentello DC et al. | — | 2024 | → |
| Neuropathogenesis-on-chips for neurodegenerative diseases. | Amartumur S et al. | — | 2024 | → |
| Neuropathological changes in the TASTPM mouse model of Alzheimer's disease and their relation to hyperexcitability and cortical spreading depolarization. | Gimeno-Ferrer F et al. | — | 2024 | → |
| New approaches for understanding the potential role of microbes in Alzheimer's disease. | Whitson HE et al. | — | 2024 | → |
| Novel Approaches to Studying SLC13A5 Disease. | Beltran AS | — | 2024 | → |
| On the Inadequacy of the Current Transgenic Animal Models of Alzheimer's Disease: The Path Forward. | Volloch V et al. | — | 2024 | → |
| Polysaccharides from <i>Basella alba</i> Protect Post-Mitotic Neurons against Cell Cycle Re-Entry and Apoptosis Induced by the Amyloid-Beta Peptide by Blocking Sonic Hedgehog Expression. | Hou BY et al. | — | 2024 | → |
| Pros and Cons of Human Brain Organoids to Study Alzheimer's Disease. | Sainz A et al. | — | 2024 | → |
| P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy. | Zhang D et al. | — | 2024 | → |
| Quintessential Synergy: Concurrent Transient Administration of Integrated Stress Response Inhibitors and BACE1 and/or BACE2 Activators as the Optimal Therapeutic Strategy for Alzheimer's Disease. | Volloch V et al. | — | 2024 | → |
| Rational Design of Dual-Functionalized Gd@C<sub>82</sub> Nanoparticles to Relieve Neuronal Cytotoxicity in Alzheimer's Disease via Inhibition of Aβ Aggregation. | Yin X et al. | — | 2024 | → |
| Retinal Organoids: A Next-Generation Platform for High-Throughput Drug Discovery. | Zhao H et al. | — | 2024 | → |
| Simple modeling of familial Alzheimer's disease using human pluripotent stem cell-derived cerebral organoid technology. | Choe MS et al. | — | 2024 | → |
| Structure-Based Discovery of A Small Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) that Significantly Reduces Alzheimer's Disease Neuropathology. | Mondal P et al. | — | 2024 | → |
| Tackling neurodegeneration <i>in vitro</i> with omics: a path towards new targets and drugs. | Carraro C et al. | — | 2024 | → |
| TFR1 knockdown alleviates iron overload and mitochondrial dysfunction during neural differentiation of Alzheimer's disease-derived induced pluripotent stem cells by interacting with GSK3B. | Kang T et al. | — | 2024 | → |
| The Co-oligomers of Aβ42 and Human Islet Amyloid Polypeptide Exacerbate Neurotoxicity and Alzheimer-like Pathology at Cellular Level. | Deng J et al. | — | 2024 | → |
| The organoid modeling approach to understanding the mechanisms underlying neurodegeneration: A comprehensive review. | Jalali H et al. | — | 2024 | → |
| TNF⍺-driven Aβ aggregation, synaptic dysfunction and hypermetabolism in human iPSC-derived cortical neurons | Díaz AG et al. | — | 2024 | — |
| Unlocking the Potential of Human-Induced Pluripotent Stem Cells: Cellular Responses and Secretome Profiles in Peptide Hydrogel 3D Culture. | Cui M et al. | — | 2024 | → |
| Updates in Alzheimer's disease: from basic research to diagnosis and therapies. | Liu E et al. | — | 2024 | → |
| Vascular Heparan Sulfate and Amyloid-β in Alzheimer's Disease Patients. | McMillan IO et al. | — | 2024 | → |
| 3D cell culture model: From ground experiment to microgravity study. | Ma C et al. | — | 2023 | → |
| AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C. | Georgiou E et al. | — | 2023 | → |
| Accelerating aging with dynamic biomaterials: Recapitulating aged tissue phenotypes in engineered platforms. | Madl CM | — | 2023 | → |
| Accelerating the in vitro emulation of Alzheimer's disease-associated phenotypes using a novel 3D blood-brain barrier neurosphere co-culture model. | Ko EC et al. | — | 2023 | → |
| Adeno-associated virus (AAV) 9-mediated gene delivery of Nurr1 and Foxa2 ameliorates symptoms and pathologies of Alzheimer disease model mice by suppressing neuro-inflammation and glial pathology. | Yang Y et al. | — | 2023 | → |
| Advances in current <i>in vitro</i> models on neurodegenerative diseases. | Pereira I et al. | — | 2023 | → |
| Advances in development of exosomes for ophthalmic therapeutics. | Tian Y et al. | — | 2023 | → |
| Altered ubiquitin signaling induces Alzheimer's disease-like hallmarks in a three-dimensional human neural cell culture model. | Maniv I et al. | — | 2023 | → |
| Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells? | Rodriguez-Jimenez FJ et al. | — | 2023 | → |
| Analysis of the interplay between MeCP2 and histone H1 during <i>in vitro</i> differentiation of human ReNCell neural progenitor cells. | Siqueira E et al. | — | 2023 | → |
| A new perspective on Alzheimer's disease: m6A modification. | Xia L et al. | — | 2023 | → |
| APP mediates tau uptake and its overexpression leads to the exacerbated tau pathology. | Chen J et al. | — | 2023 | → |
| Artificial intelligence for neurodegenerative experimental models. | Marzi SJ et al. | — | 2023 | → |
| Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. | Therriault J et al. | — | 2023 | → |
| A three-dimensional spheroid co-culture system of neurons and astrocytes derived from Alzheimer's disease patients for drug efficacy testing. | Park H et al. | — | 2023 | → |
| BACE2: A Promising Neuroprotective Candidate for Alzheimer's Disease. | Yeap YJ et al. | — | 2023 | → |
| Bibliometric analysis of cerebral organoids and diseases in the last 10 years. | Luo BY et al. | — | 2023 | → |
| Calcium Signaling during Cortical Apical Dendrite Initiation: A Role for Cajal-Retzius Neurons. | Enck JR et al. | — | 2023 | → |
| Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimer's Disease from 2004 to 2022. | Wang R et al. | — | 2023 | → |
| Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms. | Sreenivasamurthy S et al. | — | 2023 | → |
| Development of an accelerated cellular model for early changes in Alzheimer's disease. | Xue H et al. | — | 2023 | → |
| Differentiated cultures of an immortalized human neural progenitor cell line do not replicate prions despite PrP<sup>C</sup> overexpression. | Slota JA et al. | — | 2023 | → |
| Efficient generation of brain organoids using magnetized gold nanoparticles. | Kim H et al. | — | 2023 | → |
| Emerging concepts towards a translational framework in Alzheimer's disease. | Cozachenco D et al. | — | 2023 | → |
| Engineering Neurovascular Unit and Blood-Brain Barrier for Ischemic Stroke Modeling. | Liu Z et al. | — | 2023 | → |
| Evaluation of bumetanide as a potential therapeutic agent for Alzheimer's disease. | Boyarko B et al. | — | 2023 | → |
| Evaluation of Cell-Specific Alterations in Alzheimer's Disease and Relevance of In Vitro Models. | Guido G et al. | — | 2023 | → |
| Exploring the Pathophysiology of Delirium: An Overview of Biomarker Studies, Animal Models, and Tissue-Engineered Models. | McKay TB et al. | — | 2023 | → |
| Functional bioengineered tissue models of neurodegenerative diseases. | Mullis AS et al. | — | 2023 | → |
| Heparan sulfate proteoglycan in Alzheimer's disease: aberrant expression and functions in molecular pathways related to amyloid-β metabolism. | Ozsan McMillan I et al. | — | 2023 | → |
| Herpes Simplex Virus Type 1 Induces AD-like Neurodegeneration Markers in Human Progenitor and Differentiated ReNcell VM Cells. | Salgado B et al. | — | 2023 | → |
| Human 3D brain organoids: steering the demolecularization of brain and neurological diseases. | Adlakha YK | — | 2023 | → |
| Human brain organoid code of conduct. | Hoppe M et al. | — | 2023 | → |
| Human-Derived Cortical Neurospheroids Coupled to Passive, High-Density and 3D MEAs: A Valid Platform for Functional Tests. | Muzzi L et al. | — | 2023 | → |
| Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons and Glia for the Elucidation of Pathogenic Mechanisms in Alzheimer's Disease. | Young JE et al. | — | 2023 | → |
| Improving the Bioavailability and Efficacy of Coenzyme Q10 on Alzheimer's Disease Through the Arginine Based Proniosomes. | Ergin AD et al. | — | 2023 | → |
| Infiltrating CD8<sup>+</sup> T cells exacerbate Alzheimer's disease pathology in a 3D human neuroimmune axis model. | Jorfi M et al. | — | 2023 | → |
| Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases. | Nainu F et al. | — | 2023 | → |
| Inhibition of insulin-degrading enzyme in human neurons promotes amyloid-β deposition. | Rowland HA et al. | — | 2023 | → |
| In vitro induction of in vivo-relevant stellate astrocytes in 3D brain-derived, decellularized extracellular matrices. | Han S et al. | — | 2023 | → |
| [iPS cell technologies toward overcoming neurological diseases]. | Kimura T et al. | — | 2023 | → |
| Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling. | Kim E et al. | — | 2023 | → |
| Late-life sleep duration associated with amnestic mild cognitive impairment. | Yuan M et al. | — | 2023 | → |
| Lowering levels of reelin in entorhinal cortex layer II-neurons results in lowered levels of intracellular amyloid-β. | Kobro-Flatmoen A et al. | — | 2023 | → |
| Low glucose induced Alzheimer's disease-like biochemical changes in human induced pluripotent stem cell-derived neurons is due to dysregulated O-GlcNAcylation. | Huang CW et al. | — | 2023 | → |
| MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer's disease. | Balusu S et al. | — | 2023 | → |
| Molecular Insights into Cell Type-specific Roles in Alzheimer's Disease: Human Induced Pluripotent Stem Cell-based Disease Modelling. | Qu W et al. | — | 2023 | → |
| Multi-target regulatory mechanism of Yang Xin Tang - a traditional Chinese medicine against dementia. | Lo TY et al. | — | 2023 | → |
| Network Bursts in 3D Neuron Clusters Cultured on Microcontact-Printed Substrates. | Liang Q et al. | — | 2023 | → |
| Newly Synthesized Creatine Derivatives as Potential Neuroprotective and Antioxidant Agents on In Vitro Models of Parkinson's Disease. | Kostadinova I et al. | — | 2023 | → |
| Organoid assessment technologies. | Gu Y et al. | — | 2023 | → |
| Organoids for modeling prion diseases. | Walters RO et al. | — | 2023 | → |
| Potential Regulatory Role of miR-21 on Alzheimer's Disease by Targeting GSK-3β Signaling. | Ding H | — | 2023 | → |
| Protective Alzheimer's disease-associated APP A673T variant predominantly decreases sAPPβ levels in cerebrospinal fluid and 2D/3D cell culture models. | Wittrahm R et al. | — | 2023 | → |
| Role for cell death pathway in Alzheimer's disease. | Sirkis DW et al. | — | 2023 | → |
| Role of primary aging hallmarks in Alzheimer´s disease. | Zhao J et al. | — | 2023 | → |
| Substitution of PINK1 Gly411 modulates substrate receptivity and turnover. | Fiesel FC et al. | — | 2023 | → |
| Susceptibility of Ovine Bone Marrow-Derived Mesenchymal Stem Cell Spheroids to Scrapie Prion Infection. | Hernaiz A et al. | — | 2023 | → |
| Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change. | McMillan PJ et al. | — | 2023 | → |
| The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells. | Cai W et al. | — | 2023 | → |
| The Amyloid Cascade Hypothesis 2.0 for Alzheimer's Disease and Aging-Associated Cognitive Decline: From Molecular Basis to Effective Therapy. | Volloch V et al. | — | 2023 | → |
| The Amyloid Cascade Hypothesis 2.0: Generalization of the Concept. | Volloch V et al. | — | 2023 | → |
| The Biological Behaviors of Neural Stem Cell Affected by Microenvironment from Host Organotypic Brain Slices under Different Conditions. | Jiao Q et al. | — | 2023 | → |
| The Function, Underlying Mechanism and Clinical Potential of Exosomes in Colorectal Cancer. | Han J et al. | — | 2023 | → |
| The Multifaceted Role of WNT Signaling in Alzheimer's Disease Onset and Age-Related Progression. | Kostes WW et al. | — | 2023 | → |
| Thin-film conformal fluorescent SU8-phenylenediamine. | Barhum H et al. | — | 2023 | → |
| Three-dimensional bioprinting of stem cell-derived central nervous system cells enables astrocyte growth, vasculogenesis, and enhances neural differentiation/function. | Sullivan MA et al. | — | 2023 | → |
| Tools for studying human microglia: In vitro and in vivo strategies. | Warden AS et al. | — | 2023 | → |
| Two-step method fabricating a 3D nerve cell model with brain-like mechanical properties and tunable porosity vascular structures via coaxial printing. | Wang Z et al. | — | 2023 | → |
| Unlocking Neural Function with 3D In Vitro Models: A Technical Review of Self-Assembled, Guided, and Bioprinted Brain Organoids and Their Applications in the Study of Neurodevelopmental and Neurodegenerative Disorders. | D'Antoni C et al. | — | 2023 | → |
| Use of <i>in vitro</i> derived human neuronal models to study host-parasite interactions of <i>Toxoplasma gondii</i> in neurons and neuropathogenesis of chronic toxoplasmosis. | Halonen SK | — | 2023 | → |
| A 3D-induced pluripotent stem cell-derived human neural culture model to study certain molecular and biochemical aspects of Alzheimer's disease. | Prasannan P et al. | — | 2022 | → |
| A Comprehensive Update of Cerebral Organoids between Applications and Challenges. | Li X et al. | — | 2022 | → |
| A Ctnnb1 enhancer regulates neocortical neurogenesis by controlling the abundance of intermediate progenitors. | Wang J et al. | — | 2022 | → |
| Advances in Recapitulating Alzheimer's Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models. | Hasan MF et al. | — | 2022 | → |
| Alteration in the Synaptic and Extrasynaptic Organization of AMPA Receptors in the Hippocampus of P301S Tau Transgenic Mice. | Alfaro-Ruiz R et al. | — | 2022 | → |
| Alzheimer's disease amyloid-β pathology in the lens of the eye. | Moncaster JA et al. | — | 2022 | → |
| A Matrigel-based 3D construct of SH-SY5Y cells models the α-synuclein pathologies of Parkinson's disease. | Li ZF et al. | — | 2022 | → |
| Amyloid Aβ<sub>25-35</sub> Aggregates Say 'NO' to Long-Term Potentiation in the Hippocampus through Activation of Stress-Induced Phosphatase 1 and Mitochondrial Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger. | Maltsev AV et al. | — | 2022 | → |
| Amyloid beta accumulations and enhanced neuronal differentiation in cerebral organoids of Dutch-type cerebral amyloid angiopathy patients. | Daoutsali E et al. | — | 2022 | → |
| Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease. | Roda AR et al. | — | 2022 | → |
| A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer. | Shimada H et al. | — | 2022 | → |
| Animal and Cellular Models of Alzheimer's Disease: Progress, Promise, and Future Approaches. | Trujillo-Estrada L et al. | — | 2022 | → |
| An insight into the iPSCs-derived two-dimensional culture and three-dimensional organoid models for neurodegenerative disorders. | Bhargava A et al. | — | 2022 | → |
| An in vitro workflow of neuron-laden agarose-laminin hydrogel for studying small molecule-induced amyloidogenic condition. | Namchaiw P et al. | — | 2022 | → |
| Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. | Baxi EG et al. | — | 2022 | → |
| Application and prospects of high-throughput screening for <i>in vitro</i> neurogenesis. | Zhang SY et al. | — | 2022 | → |
| A primary rodent triculture model to investigate the role of glia-neuron crosstalk in regulation of neuronal activity. | Phadke L et al. | — | 2022 | → |
| A simple human cell model for TAU trafficking and tauopathy-related TAU pathology. | Bell M et al. | — | 2022 | → |
| A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies. | Wasielewska JM et al. | — | 2022 | → |
| Association of the Protein-Quality-Control Protein Ubiquilin-1 With Alzheimer's Disease Both <i>in vitro</i> and <i>in vivo</i>. | Zhang C et al. | — | 2022 | → |
| Bioengineered models of Parkinson's disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment. | Fiore NJ et al. | — | 2022 | → |
| Biomaterials-based strategies for <i>in vitro</i> neural models. | Ozgun A et al. | — | 2022 | → |
| Blood-brain barrier (BBB)-on-a-chip: a promising breakthrough in brain disease research. | Peng B et al. | — | 2022 | → |
| Bone Tissue and the Nervous System: What Do They Have in Common? | Minoia A et al. | — | 2022 | → |
| Brain and Retinal Organoids for Disease Modeling: The Importance of In Vitro Blood-Brain and Retinal Barriers Studies. | Martinelli I et al. | — | 2022 | → |
| Brain organoids: Establishment and application. | Chen H et al. | — | 2022 | → |
| Building in vitro models of the brain to understand the role of <i>APOE</i> in Alzheimer's disease. | Pinals RL et al. | — | 2022 | → |
| Capturing the third dimension in drug discovery: Spatially-resolved tools for interrogation of complex 3D cell models. | Simão D et al. | — | 2022 | → |
| Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 signaling. | Wang HJ et al. | — | 2022 | → |
| Cell models for Alzheimer's and Parkinson's disease: At the interface of biology and drug discovery. | Cetin S et al. | — | 2022 | → |
| Cell models for Down syndrome-Alzheimer's disease research. | Wu Y et al. | — | 2022 | → |
| Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities. | Lange J et al. | — | 2022 | → |
| Cerebral Organoids as an Experimental Platform for Human Neurogenomics. | Nowakowski TJ et al. | — | 2022 | → |
| Challenges of Organoid Research. | Andrews MG et al. | — | 2022 | → |
| Comprehensive Characterization of CK1δ-Mediated Tau Phosphorylation in Alzheimer's Disease. | Roth A et al. | — | 2022 | → |
| Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer's disease and related dementias. | Yin Z et al. | — | 2022 | → |
| Crry silencing alleviates Alzheimer's disease injury by regulating neuroinflammatory cytokines and the complement system. | Zhu XC et al. | — | 2022 | → |
| Culture Variabilities of Human iPSC-Derived Cerebral Organoids Are a Major Issue for the Modelling of Phenotypes Observed in Alzheimer's Disease. | Hernández D et al. | — | 2022 | → |
| Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases. | Yoshida S et al. | — | 2022 | → |
| Degradation and inhibition of epigenetic regulatory protein BRD4 exacerbate Alzheimer's disease-related neuropathology in cell models. | Zhang S et al. | — | 2022 | → |
| Dissecting the complexities of Alzheimer disease with in vitro models of the human brain. | Blanchard JW et al. | — | 2022 | → |
| DNA Damage Increases Secreted Aβ40 and Aβ42 in Neuronal Progenitor Cells: Relevance to Alzheimer's Disease. | Welty S et al. | — | 2022 | → |
| DNGR-1-tracing marks an ependymal cell subset with damage-responsive neural stem cell potential. | Frederico B et al. | — | 2022 | → |
| Engineered Aging Cardiac Tissue Chip Model for Studying Cardiovascular Disease. | Budhathoki S et al. | — | 2022 | → |
| Epithelial Cells in 2D and 3D Cultures Exhibit Large Differences in Higher-order Genomic Interactions. | Liu X et al. | — | 2022 | → |
| Exploring the neurogenic differentiation of human dental pulp stem cells. | Al-Maswary AA et al. | — | 2022 | → |
| Expression-based Genome-wide Association Study Links OPN and IL1-RA With Newly Diagnosed Type 1 Diabetes in Children. | Jia X et al. | — | 2022 | → |
| Functional mechanical attributes of natural and synthetic gel-based scaffolds in tissue engineering: strain-stiffening effects on apparent elastic modulus and compressive toughness. | Schiavi A et al. | — | 2022 | → |
| GPCR kinases generate an APH1A phosphorylation barcode to regulate amyloid-β generation. | Todd NK et al. | — | 2022 | → |
| Harnessing cerebral organoids for Alzheimer's disease research. | Bubnys A et al. | — | 2022 | → |
| Herpes Simplex Virus Infection Increases Beta-Amyloid Production and Induces the Development of Alzheimer's Disease. | Ge T et al. | — | 2022 | → |
| Heterotypic interactions in amyloid function and disease. | Konstantoulea K et al. | — | 2022 | → |
| Human cerebral organoids - a new tool for clinical neurology research. | Eichmüller OL et al. | — | 2022 | → |
| Human iPSC-Derived Neural Models for Studying Alzheimer's Disease: from Neural Stem Cells to Cerebral Organoids. | Barak M et al. | — | 2022 | → |
| Impact of the Flavonoid Quercetin on β-Amyloid Aggregation Revealed by Intrinsic Fluorescence. | Alghamdi A et al. | — | 2022 | → |
| Infection and inflammation: New perspectives on Alzheimer's disease. | Whitson HE et al. | — | 2022 | → |
| Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity. | Vojtechova I et al. | — | 2022 | → |
| Influence of Simulated Deep Brain Stimulation on the Expression of Inflammatory Mediators by Human Central Nervous System Cells In Vitro. | Kubelt C et al. | — | 2022 | → |
| Inhibiting Autophagy Pathway of PI3K/AKT/mTOR Promotes Apoptosis in SK-N-SH Cell Model of Alzheimer's Disease. | Pang Y et al. | — | 2022 | → |
| In Vitro Methodologies to Study the Role of Advanced Glycation End Products (AGEs) in Neurodegeneration. | Chrysanthou M et al. | — | 2022 | → |
| Microfabricated disk technology: Rapid scale up in midbrain organoid generation. | Mohamed NV et al. | — | 2022 | → |
| Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality. | Sabate-Soler S et al. | — | 2022 | → |
| Mitigating Effect of Estrogen in Alzheimer's Disease-Mimicking Cerebral Organoid. | Kim JY et al. | — | 2022 | → |
| Modeling neurodegenerative diseases with cerebral organoids and other three-dimensional culture systems: focus on Alzheimer's disease. | Venkataraman L et al. | — | 2022 | → |
| Neurodegeneration and convergent factors contributing to the deterioration of the cytoskeleton in Alzheimer's disease, cerebral ischemia and multiple sclerosis (Review). | Gutiérrez-Vargas JA et al. | — | 2022 | → |
| Neuroimmune contributions to Alzheimer's disease: a focus on human data. | Haage V et al. | — | 2022 | → |
| Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype? | Targa Dias Anastacio H et al. | — | 2022 | → |
| Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer's Disease. | Ning S et al. | — | 2022 | → |
| Organoids: A new approach in toxicity testing of nanotherapeutics. | Nabi SU et al. | — | 2022 | → |
| Orgo-Seq integrates single-cell and bulk transcriptomic data to identify cell type specific-driver genes associated with autism spectrum disorder. | Lim ET et al. | — | 2022 | → |
| Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling. | Grekhnev DA et al. | — | 2022 | → |
| Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease. | Nelson AR | — | 2022 | → |
| Physical Exercise, a Potential Non-Pharmacological Intervention for Attenuating Neuroinflammation and Cognitive Decline in Alzheimer's Disease Patients. | Ribarič S | — | 2022 | → |
| Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. | Kang MS et al. | — | 2022 | → |
| Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons. | Capano LS et al. | — | 2022 | → |
| Recent advances in optical imaging through deep tissue: imaging probes and techniques. | Yoon S et al. | — | 2022 | → |
| Screening neuroprotective compounds in herpes-induced Alzheimer's disease cell and 3D tissue models. | Silveira IA et al. | — | 2022 | → |
| Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model. | Rickner HD et al. | — | 2022 | → |
| Structural biology of cell surface receptors implicated in Alzheimer's disease. | Hermans SJ et al. | — | 2022 | → |
| Synaptic dysfunction in early phases of Alzheimer's Disease. | Pelucchi S et al. | — | 2022 | → |
| Synthetic amyloid beta does not induce a robust transcriptional response in innate immune cell culture systems. | Quiroga IY et al. | — | 2022 | → |
| The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimer's Disease and for Its Potential Cure at Symptomatic Stages. | Volloch V et al. | — | 2022 | → |
| The cellular model for Alzheimer's disease research: PC12 cells. | Xie D et al. | — | 2022 | → |
| The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. | Frisoni GB et al. | — | 2022 | → |
| The role of Aβ in Alzheimer's Disease as an Evolutionary Outcome of Optimized Innate Immune Defense. | Tatar M | — | 2022 | → |
| Three-dimensional-engineered bioprinted <i>in vitro</i> human neural stem cell self-assembling culture model constructs of Alzheimer's disease. | Zhang Y et al. | — | 2022 | → |
| Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays? | Sala-Jarque J et al. | — | 2022 | → |
| Transcription-associated DNA DSBs activate p53 during hiPSC-based neurogenesis. | Michel N et al. | — | 2022 | → |
| Unraveling pathological mechanisms in neurological disorders: the impact of cell-based and organoid models. | Langlie J et al. | — | 2022 | → |
| Unraveling the Mechanobiology Underlying Traumatic Brain Injury with Advanced Technologies and Biomaterials. | Shao X et al. | — | 2022 | → |
| USP10 deubiquitinates Tau, mediating its aggregation. | Wei Z et al. | — | 2022 | → |
| Viable human brain microvessels for the study of aging and neurodegenerative diseases. | Damodarasamy M et al. | — | 2022 | → |
| 3D biomaterial models of human brain disease. | Kajtez J et al. | — | 2021 | → |
| 3D hydrogel models of the neurovascular unit to investigate blood-brain barrier dysfunction. | Potjewyd G et al. | — | 2021 | → |
| 3D spheroids of human placenta-derived mesenchymal stem cells attenuate spinal cord injury in mice. | Deng J et al. | — | 2021 | → |
| Active constituent of Polygala tenuifolia attenuates cognitive deficits by rescuing hippocampal neurogenesis in APP/PS1 transgenic mice. | Wang XF et al. | — | 2021 | → |
| Activity-dependent release of phosphorylated human tau from Drosophila neurons in primary culture. | Ismael S et al. | — | 2021 | → |
| Advances in Central Nervous System Organoids: A Focus on Organoid-Based Models for Motor Neuron Disease. | Vieira de Sá R et al. | — | 2021 | → |
| Advances in microfluidic in vitro systems for neurological disease modeling. | Holloway PM et al. | — | 2021 | → |
| A logical network-based drug-screening platform for Alzheimer's disease representing pathological features of human brain organoids. | Park JC et al. | — | 2021 | → |
| Alternative platelet activation pathways and their role in neurodegenerative diseases. | Ferrer-Raventós P et al. | — | 2021 | → |
| Alzheimer's Disease: Current Perspectives and Advances in Physiological Modeling. | Josephine Boder E et al. | — | 2021 | → |
| Applications of brain organoids in neurodevelopment and neurological diseases. | Sun N et al. | — | 2021 | → |
| Assessment of the Effects of Altered Amyloid-Beta Clearance on Behavior following Repeat Closed-Head Brain Injury in Amyloid-Beta Precursor Protein Humanized Mice. | Maigler KC et al. | — | 2021 | → |
| Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease. | McAlpine CS et al. | — | 2021 | → |
| Axonal generation of amyloid-β from palmitoylated APP in mitochondria-associated endoplasmic reticulum membranes. | Bhattacharyya R et al. | — | 2021 | → |
| Bioengineering Approaches for the Advanced Organoid Research. | Yi SA et al. | — | 2021 | → |
| Biologia Futura: the importance of 3D organoids-a new approach for research on neurological and rare diseases. | Akbaba TH et al. | — | 2021 | → |
| Brain organoids: A promising model to assess oxidative stress-induced central nervous system damage. | Oyefeso FA et al. | — | 2021 | → |
| Brain Organoids: Studying Human Brain Development and Diseases in a Dish. | Xu J et al. | — | 2021 | → |
| Brain Organoids: Tiny Mirrors of Human Neurodevelopment and Neurological Disorders. | Yadav A et al. | — | 2021 | → |
| Building the brain from scratch: Engineering region-specific brain organoids from human stem cells to study neural development and disease. | Jacob F et al. | — | 2021 | → |
| Can platelet activation result in increased plasma Aβ levels and contribute to the pathogenesis of Alzheimer's disease? | Carbone MG et al. | — | 2021 | → |
| Chronic and Acute Manipulation of Cortical Glutamate Transmission Induces Structural and Synaptic Changes in Co-cultured Striatal Neurons. | Kuhlmann N et al. | — | 2021 | → |
| Construction of a 3D brain extracellular matrix model to study the interaction between microglia and T cells in co-culture. | Frühauf M et al. | — | 2021 | → |
| Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. | Oakley DH et al. | — | 2021 | → |
| Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology? | Vignon A et al. | — | 2021 | → |
| Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models. | Cenini G et al. | — | 2021 | → |
| Emerging Brain-Pathophysiology-Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip. | Bang S et al. | — | 2021 | → |
| Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases. | Trudler D et al. | — | 2021 | → |
| Engineered Human Induced Pluripotent Cells Enable Genetic Code Expansion in Brain Organoids. | van Husen LS et al. | — | 2021 | → |
| Engineering <i>in vitro</i> human neural tissue analogs by 3D bioprinting and electrostimulation. | Warren D et al. | — | 2021 | → |
| Engineering organoids. | Hofer M et al. | — | 2021 | → |
| Evaluation of Fluorinated Cromolyn Derivatives as Potential Therapeutics for Alzheimer's Disease. | Shoup TM et al. | — | 2021 | → |
| Fabrication and Characterization of 3D Printed, 3D Microelectrode Arrays for Interfacing with a Peripheral Nerve-on-a-Chip. | Kundu A et al. | — | 2021 | → |
| Fabrication techniques of biomimetic scaffolds in three-dimensional cell culture: A review. | Badekila AK et al. | — | 2021 | → |
| Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation. | Wang H et al. | — | 2021 | → |
| Genome-encoded cytoplasmic double-stranded RNAs, found in <i>C9ORF72</i> ALS-FTD brain, propagate neuronal loss. | Rodriguez S et al. | — | 2021 | → |
| High-Throughput Screening of Compound Neurotoxicity Using 3D-Cultured Neural Stem Cells on a 384-Pillar Plate. | Kang SY et al. | — | 2021 | → |
| Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery. | Qian L et al. | — | 2021 | → |
| Human mini-brain models. | Tan HY et al. | — | 2021 | → |
| <i>In Vitro</i> Development of Human iPSC-Derived Functional Neuronal Networks on Laser-Fabricated 3D Scaffolds. | Koroleva A et al. | — | 2021 | → |
| Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia. | Bassil R et al. | — | 2021 | → |
| Increased maturation of iPSC-derived neurons in a hydrogel-based 3D culture. | de Leeuw SM et al. | — | 2021 | → |
| Intranasally Administered L-Myc-Immortalized Human Neural Stem Cells Migrate to Primary and Distal Sites of Damage after Cortical Impact and Enhance Spatial Learning. | Gutova M et al. | — | 2021 | → |
| In vitro comparison of major memory-support dietary supplements for their effectiveness in reduction/inhibition of beta-amyloid protein fibrils and tau protein tangles: key primary targets for memory loss. | Snow AD et al. | — | 2021 | → |
| In Vitro Studies on Therapeutic Effects of Cannabidiol in Neural Cells: Neurons, Glia, and Neural Stem Cells. | Kim J et al. | — | 2021 | → |
| Klotho inhibits neuronal senescence in human brain organoids. | Shaker MR et al. | — | 2021 | → |
| Label-free monitoring of 3D cortical neuronal growth <i>in vitro</i> using optical diffraction tomography. | Lee AJ et al. | — | 2021 | → |
| Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer's Disease Pathology and Improve Cognitive Deficits. | Chen YA et al. | — | 2021 | → |
| Mitochondria-Microbiota Interaction in Neurodegeneration. | Kramer P | — | 2021 | → |
| Modeling Aβ42 Accumulation in Response to Herpes Simplex Virus 1 Infection: 2D or 3D? | Abrahamson EE et al. | — | 2021 | → |
| Modeling brain development and diseases with human cerebral organoids. | Shi Y et al. | — | 2021 | → |
| Modeling neurological disorders using brain organoids. | Zhang DY et al. | — | 2021 | → |
| Modelling neurodegenerative disease using brain organoids. | Wray S | — | 2021 | → |
| Nanogold induces anti-inflammation against oxidative stress induced in human neural stem cells exposed to amyloid-beta peptide. | Chiang MC et al. | — | 2021 | → |
| Neural In Vitro Models for Studying Substances Acting on the Central Nervous System. | Fritsche E et al. | — | 2021 | → |
| Neurodegenerative brain models vs. cell replacement or restoration therapy: A review on promises and pitfalls. | Kumar D et al. | — | 2021 | → |
| Neuromuscular Development and Disease: Learning From <i>in vitro</i> and <i>in vivo</i> Models. | Fralish Z et al. | — | 2021 | → |
| News from Mars: Two-Tier Paradox, Intracellular PCR, Chimeric Junction Shift, Dark Matter mRNA and Other Remarkable Features of Mammalian RNA-Dependent mRNA Amplification. Implications for Alzheimer's Disease, RNA-Based Vaccines and mRNA Therapeutics. | Volloch V et al. | — | 2021 | → |
| Nontraditional systems in aging research: an update. | Mikuła-Pietrasik J et al. | — | 2021 | → |
| Novel fragile X syndrome 2D and 3D brain models based on human isogenic FMRP-KO iPSCs. | Brighi C et al. | — | 2021 | → |
| Optimization of cerebral organoids: a more qualified model for Alzheimer's disease research. | Bi FC et al. | — | 2021 | → |
| Organoids: An Emerging Tool to Study Aging Signature across Human Tissues. Modeling Aging with Patient-Derived Organoids. | Torrens-Mas M et al. | — | 2021 | → |
| Patterning of interconnected human brain spheroids. | Kim JJ et al. | — | 2021 | → |
| Phenotypic screening system using three-dimensional (3D) culture models for natural product screening. | Suenaga H et al. | — | 2021 | → |
| Reactive Astrocytes Contribute to Alzheimer's Disease-Related Neurotoxicity and Synaptotoxicity in a Neuron-Astrocyte Co-culture Assay. | Wasilewski D et al. | — | 2021 | → |
| Reconstituting neurovascular unit with primary neural stem cells and brain microvascular endothelial cells in three-dimensional matrix. | Wang H et al. | — | 2021 | → |
| Stem cell-derived three-dimensional (organoid) models of Alzheimer's disease: a precision medicine approach. | Kim SJ et al. | — | 2021 | → |
| Synthetic amyloid-β oligomers drive early pathological progression of Alzheimer's disease in nonhuman primates. | Yue F et al. | — | 2021 | → |
| Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease. | Fulop T et al. | — | 2021 | → |
| Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. | Chen XQ et al. | — | 2021 | → |
| Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. | Koh HS et al. | — | 2021 | → |
| The Amyloid-β Pathway in Alzheimer's Disease. | Hampel H et al. | — | 2021 | → |
| The Unifying Hypothesis of Alzheimer's Disease: Heparan Sulfate Proteoglycans/Glycosaminoglycans Are Key as First Hypothesized Over 30 Years Ago. | Snow AD et al. | — | 2021 | → |
| Towards Advanced iPSC-based Drug Development for Neurodegenerative Disease. | Pasteuning-Vuhman S et al. | — | 2021 | → |
| Toward three-dimensional <i>in vitro</i> models to study neurovascular unit functions in health and disease. | Caffrey TM et al. | — | 2021 | → |
| Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia. | Albert K et al. | — | 2021 | → |
| Velvet antler polypeptide-loaded polyvinyl alcohol-sodium alginate hydrogels promote the differentiation of neural progenitor cells in 3D towards oligodendrocytes in vitro. | Ma S et al. | — | 2021 | → |
| What is the gold standard model for Alzheimer's disease drug discovery and development? | Cacabelos R et al. | — | 2021 | → |
| 3D brain tissue physiological model with co-cultured primary neurons and glial cells in hydrogels. | Raimondi I et al. | — | 2020 | → |
| A 3D human brain-like tissue model of herpes-induced Alzheimer's disease. | Cairns DM et al. | — | 2020 | → |
| A co-culture nanofibre scaffold model of neural cell degeneration in relevance to Parkinson's disease. | Chemmarappally JM et al. | — | 2020 | → |
| A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise. | Pearse Y et al. | — | 2020 | → |
| A CX3CR1 Reporter hESC Line Facilitates Integrative Analysis of In-Vitro-Derived Microglia and Improved Microglia Identity upon Neuron-Glia Co-culture. | Grubman A et al. | — | 2020 | → |
| Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. | Volpato V et al. | — | 2020 | → |
| Advanced Materials to Enhance Central Nervous System Tissue Modeling and Cell Therapy. | Muckom RJ et al. | — | 2020 | → |
| Advancement in the modelling and therapeutics of Parkinson's disease. | Rai SN et al. | — | 2020 | → |
| Aging-relevant human basal forebrain cholinergic neurons as a cell model for Alzheimer's disease. | Ma S et al. | — | 2020 | → |
| Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow. | Volloch V et al. | — | 2020 | → |
| Alzheimer's Disease Prevention and Treatment: Case for Optimism. | Volloch V et al. | — | 2020 | → |
| Alzheimer's Retinopathy: Seeing Disease in the Eyes. | Mirzaei N et al. | — | 2020 | → |
| A microfiber scaffold-based 3D in vitro human neuronal culture model of Alzheimer's disease. | Ranjan VD et al. | — | 2020 | → |
| A miniaturized hydrogel-based <i>in vitro</i> model for dynamic culturing of human cells overexpressing beta-amyloid precursor protein. | Tunesi M et al. | — | 2020 | → |
| Amyloid-β-independent regulators of tau pathology in Alzheimer disease. | van der Kant R et al. | — | 2020 | → |
| APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. | Zhao J et al. | — | 2020 | → |
| A Three-Dimensional Alzheimer's Disease Cell Culture Model Using iPSC-Derived Neurons Carrying A246E Mutation in PSEN1. | Hernández-Sapiéns MA et al. | — | 2020 | → |
| A three-dimensional dementia model reveals spontaneous cell cycle re-entry and a senescence-associated secretory phenotype. | Porterfield V et al. | — | 2020 | → |
| Biomaterials and Culture Systems for Development of Organoid and Organ-on-a-Chip Models. | D'Costa K et al. | — | 2020 | → |
| Brain Organoids: A Promising Living Biobank Resource for Neuroscience Research. | Li S et al. | — | 2020 | → |
| Brain organoids: Human 3D models to investigate neuronal circuits assembly, function and dysfunction. | Tambalo M et al. | — | 2020 | → |
| CAR (CARSKNKDC) Peptide Modified ReNcell-Derived Extracellular Vesicles as a Novel Therapeutic Agent for Targeted Pulmonary Hypertension Therapy. | Wang J et al. | — | 2020 | → |
| Changes in Striatal Medium Spiny Neuron Morphology Resulting from Dopamine Depletion Are Reversible. | Witzig VS et al. | — | 2020 | → |
| Collagen hydrogel confinement of Amyloid-β (Aβ) accelerates aggregation and reduces cytotoxic effects. | Simpson LW et al. | — | 2020 | → |
| Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease. | Aksnes M et al. | — | 2020 | → |
| Compound-based Chinese medicine formula: From discovery to compatibility mechanism. | Luan X et al. | — | 2020 | → |
| Dendritic Spines in Alzheimer's Disease: How the Actin Cytoskeleton Contributes to Synaptic Failure. | Pelucchi S et al. | — | 2020 | → |
| Dietary Fatty Acid Factors in Alzheimer's Disease: A Review. | Zhang T et al. | — | 2020 | → |
| Emerging technologies to study glial cells. | Hirbec H et al. | — | 2020 | → |
| From beta amyloid to altered proteostasis in Alzheimer's disease. | Bruni AC et al. | — | 2020 | → |
| From in vitro to in vivo reprogramming for neural transdifferentiation: An approach for CNS tissue remodeling using stem cell technology. | Egawa N et al. | — | 2020 | → |
| Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease. | McQuade A et al. | — | 2020 | → |
| Generating ventral spinal organoids from human induced pluripotent stem cells. | Hor JH et al. | — | 2020 | → |
| Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. | Fang J et al. | — | 2020 | → |
| High-content imaging of 3D-cultured neural stem cells on a 384-pillar plate for the assessment of cytotoxicity. | Joshi P et al. | — | 2020 | → |
| Human Dental Pulp Stem Cells Display a Potential for Modeling Alzheimer Disease-Related Tau Modifications. | Gazarian K et al. | — | 2020 | → |
| Human-Derived Brain Models: Windows into Neuropsychiatric Disorders and Drug Therapies. | Papariello A et al. | — | 2020 | → |
| Human-Induced Pluripotent Stem Cells and Herbal Small-Molecule Drugs for Treatment of Alzheimer's Disease. | Wuli W et al. | — | 2020 | → |
| Human in vitro systems for examining synaptic function and plasticity in the brain. | Lee K et al. | — | 2020 | → |
| Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. | Silva MC et al. | — | 2020 | → |
| Human Pluripotent Stem Cell-Derived Neural Cells as a Relevant Platform for Drug Screening in Alzheimer's Disease. | Garcia-Leon JA et al. | — | 2020 | → |
| If Human Brain Organoids Are the Answer to Understanding Dementia, What Are the Questions? | Ooi L et al. | — | 2020 | → |
| <i>In vitro</i> Models of Neurodegenerative Diseases. | Slanzi A et al. | — | 2020 | → |
| Impact of Four Common Hydrogels on Amyloid-β (Aβ) Aggregation and Cytotoxicity: Implications for 3D Models of Alzheimer's Disease. | Simpson LW et al. | — | 2020 | → |
| Induced pluripotent stem cells as a platform to understand patient-specific responses to opioids and anaesthetics. | Obal D et al. | — | 2020 | → |
| Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies. | Gois Beghini D et al. | — | 2020 | → |
| Innovations in 3-Dimensional Tissue Models of Human Brain Physiology and Diseases. | Lovett ML et al. | — | 2020 | → |
| In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons. | Najm R et al. | — | 2020 | → |
| Leveraging preclinical models for the development of Alzheimer disease therapeutics. | Scearce-Levie K et al. | — | 2020 | → |
| Lithium chloride reduced the level of oxidative stress in brains and serums of APP/PS1 double transgenic mice via the regulation of GSK3β/Nrf2/HO-1 pathway. | Xiang J et al. | — | 2020 | → |
| LRP::FLAG Reduces Phosphorylated Tau Levels in Alzheimer's Disease Cell Culture Models. | Cuttler K et al. | — | 2020 | → |
| Microphysiological Systems for Neurodegenerative Diseases in Central Nervous System. | Bae M et al. | — | 2020 | → |
| Microvascular Alterations in Alzheimer's Disease. | Steinman J et al. | — | 2020 | → |
| Midbrain Organoids: A New Tool to Investigate Parkinson's Disease. | Smits LM et al. | — | 2020 | → |
| Modeling Alzheimer's disease with iPSC-derived brain cells. | Penney J et al. | — | 2020 | → |
| Modeling and Targeting Alzheimer's Disease With Organoids. | Papaspyropoulos A et al. | — | 2020 | → |
| Modeling Emergent Properties in the Brain Using Tissue Models to Investigate Neurodegenerative Disease. | Harris AR et al. | — | 2020 | → |
| Modeling the complex genetic architectures of brain disease. | Fernando MB et al. | — | 2020 | → |
| Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells. | Lines G et al. | — | 2020 | → |
| Modelling neurodegenerative diseases with 3D brain organoids. | Chang Y et al. | — | 2020 | → |
| Molecular imaging of Alzheimer's disease-related gamma-secretase in mice and nonhuman primates. | Xu Y et al. | — | 2020 | → |
| Monocular Deprivation Affects Visual Cortex Plasticity Through cPKCγ-Modulated GluR1 Phosphorylation in Mice. | Zhang Y et al. | — | 2020 | → |
| Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer's. | Lopez-Barbosa N et al. | — | 2020 | → |
| Multiscale brain research on a microfluidic chip. | Zhao Y et al. | — | 2020 | → |
| Neural progenitor cell pyroptosis contributes to Zika virus-induced brain atrophy and represents a therapeutic target. | He Z et al. | — | 2020 | → |
| Neurodegeneration in a dish: advancing human stem-cell-based models of Alzheimer's disease. | Klimmt J et al. | — | 2020 | → |
| Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. | Wu Q et al. | — | 2020 | → |
| OCIAD1 contributes to neurodegeneration in Alzheimer's disease by inducing mitochondria dysfunction, neuronal vulnerability and synaptic damages. | Li X et al. | — | 2020 | → |
| Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery. | Marotta N et al. | — | 2020 | → |
| Pathological manifestation of the induced pluripotent stem cell-derived cortical neurons from an early-onset Alzheimer's disease patient carrying a presenilin-1 mutation (S170F). | Li L et al. | — | 2020 | → |
| Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration. | Morshed N et al. | — | 2020 | → |
| Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery. | Chen SD et al. | — | 2020 | → |
| Popular three-dimensional models: Advantages for cancer, Alzheimer's and cardiovascular diseases. | Ntamo Y et al. | — | 2020 | → |
| Potential of Microfluidics and Lab-on-Chip Platforms to Improve Understanding of "<i>prion-like</i>" Protein Assembly and Behavior. | Del Rio JA et al. | — | 2020 | → |
| Potential Role for Herpesviruses in Alzheimer's Disease. | Duggan MR et al. | — | 2020 | → |
| Protein folding and assembly in confined environments: Implications for protein aggregation in hydrogels and tissues. | Simpson LW et al. | — | 2020 | → |
| Recent progress in translational engineered in vitro models of the central nervous system. | Nikolakopoulou P et al. | — | 2020 | → |
| Reconstruction of Alzheimer's Disease Cell Model <i>In Vitro</i> via Extracted Peripheral Blood Molecular Cells from a Sporadic Patient. | Liu S et al. | — | 2020 | → |
| Reprogramming Fibroblasts to Neural Stem Cells by Overexpression of the Transcription Factor Ptf1a. | Jin K et al. | — | 2020 | → |
| Resolving Neurodevelopmental and Vision Disorders Using Organoid Single-Cell Multi-omics. | Brancati G et al. | — | 2020 | → |
| Retinal and Brain Organoids: Bridging the Gap Between <i>in vivo</i> Physiology and <i>in vitro</i> Micro-Physiology for the Study of Alzheimer's Diseases. | Brighi C et al. | — | 2020 | → |
| Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H<sub>2</sub>O<sub>2</sub><sup>-</sup> production. | Chun H et al. | — | 2020 | → |
| SH-SY5Y and LUHMES cells display differential sensitivity to MPP+, tunicamycin, and epoxomicin in 2D and 3D cell culture. | Ko KR et al. | — | 2020 | → |
| Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease. | Bell BJ et al. | — | 2020 | → |
| Synergy between amyloid-β and tau in Alzheimer's disease. | Busche MA et al. | — | 2020 | → |
| Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease. | Fülöp T et al. | — | 2020 | → |
| Targeting Tau Hyperphosphorylation <i>via</i> Kinase Inhibition: Strategy to Address Alzheimer's Disease. | Turab Naqvi AA et al. | — | 2020 | → |
| The Application of Brain Organoids: From Neuronal Development to Neurological Diseases. | Shou Y et al. | — | 2020 | → |
| The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. | Engstrom AK et al. | — | 2020 | → |
| The iNs and Outs of Direct Reprogramming to Induced Neurons. | Carter JL et al. | — | 2020 | → |
| The Positive Side of the Alzheimer's Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1. | Ciccone L et al. | — | 2020 | → |
| The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons. | Sharlow ER et al. | — | 2020 | → |
| The puzzle of preserved cognition in the oldest old. | Bugiani O | — | 2020 | → |
| The Role of P2X7 Receptor in Alzheimer's Disease. | Francistiová L et al. | — | 2020 | → |
| The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer's Disease Modeling. | Lee C et al. | — | 2020 | → |
| Three-dimensional modeling of human neurodegeneration: brain organoids coming of age. | Grenier K et al. | — | 2020 | → |
| Three-Dimensional Models for Studying Neurodegenerative and Neurodevelopmental Diseases. | Tsaridou S et al. | — | 2020 | → |
| Upregulation of Alzheimer's Disease Amyloid-β Protein Precursor in Astrocytes Both in vitro and in vivo. | Liang Y et al. | — | 2020 | → |
| Urolithin-A attenuates neurotoxoplasmosis and alters innate response towards predator odor. | Tan S et al. | — | 2020 | → |
| Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk. | Raman S et al. | — | 2020 | → |
| 3D bioprinting for high-throughput screening: Drug screening, disease modeling, and precision medicine applications. | Mazzocchi A et al. | — | 2019 | → |
| 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. | Bolognin S et al. | — | 2019 | → |
| A Curcumin Analog Reduces Levels of the Alzheimer's Disease-Associated Amyloid-β Protein by Modulating AβPP Processing and Autophagy. | Wan Y et al. | — | 2019 | → |
| A Human Embryonic Stem Cell Model of Aβ-Dependent Chronic Progressive Neurodegeneration. | Ubina T et al. | — | 2019 | → |
| All Together Now: Modeling the Interaction of Neural With Non-neural Systems Using Organoid Models. | Chukwurah E et al. | — | 2019 | → |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. | Long JM et al. | — | 2019 | → |
| Alzheimer's in a dish - induced pluripotent stem cell-based disease modeling. | de Leeuw S et al. | — | 2019 | → |
| Assessing drug response in engineered brain microenvironments. | Tate KM et al. | — | 2019 | → |
| Automated Live-Cell Imaging of Synapses in Rat and Human Neuronal Cultures. | Green MV et al. | — | 2019 | → |
| Blood-Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease. | Shin Y et al. | — | 2019 | → |
| Brain organoids: advances, applications and challenges. | Qian X et al. | — | 2019 | → |
| Brain organoids: a next step for humanized Alzheimer's disease models? | Gerakis Y et al. | — | 2019 | → |
| Calcilytic NPS 2143 Reduces Amyloid Secretion and Increases sAβPPα Release from PSEN1 Mutant iPSC-Derived Neurons. | Lo Giudice M et al. | — | 2019 | → |
| Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons. | van der Kant R et al. | — | 2019 | → |
| Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer's Disease Studies. | de Medeiros LM et al. | — | 2019 | → |
| Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. | Wu T et al. | — | 2019 | → |
| Convergence of human cellular models and genetics to study neural stem cell signaling to enhance central nervous system regeneration and repair. | Julian D et al. | — | 2019 | → |
| Cost-Effective Cosmetic-Grade Hyaluronan Hydrogels for ReNcell VM Human Neural Stem Cell Culture. | Ma W et al. | — | 2019 | → |
| Detection of all adult Tau isoforms in a 3D culture model of iPSC-derived neurons. | Miguel L et al. | — | 2019 | → |
| Develop a 3D neurological disease model of human cortical glutamatergic neurons using micropillar-based scaffolds. | Chen C et al. | — | 2019 | → |
| Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. | Elmaleh DR et al. | — | 2019 | → |
| Development of surface functionalization strategies for 3D-printed polystyrene constructs. | Lerman MJ et al. | — | 2019 | → |
| Differential Effects of Extracellular Vesicles of Lineage-Specific Human Pluripotent Stem Cells on the Cellular Behaviors of Isogenic Cortical Spheroids. | Marzano M et al. | — | 2019 | → |
| Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. | Pitcairn C et al. | — | 2019 | → |
| Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations. | Yao J et al. | — | 2019 | → |
| Engineering three-dimensional microenvironments towards in vitro disease models of the central nervous system. | Yildirimer L et al. | — | 2019 | → |
| Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs. | Halpern M et al. | — | 2019 | → |
| FACS-Mediated Isolation of Neuronal Cell Populations From Virus-Infected Human Embryonic Stem Cell-Derived Cerebral Organoid Cultures. | Janssens S et al. | — | 2019 | → |
| Farnesoid X Receptor (FXR) Aggravates Amyloid-β-Triggered Apoptosis by Modulating the cAMP-Response Element-Binding Protein (CREB)/Brain-Derived Neurotrophic Factor (BDNF) Pathway In Vitro. | Chen Q et al. | — | 2019 | → |
| Functional and Mechanistic Neurotoxicity Profiling Using Human iPSC-Derived Neural 3D Cultures. | Sirenko O et al. | — | 2019 | → |
| Functionalization of Brain Region-specific Spheroids with Isogenic Microglia-like Cells. | Song L et al. | — | 2019 | → |
| Gamma secretase modulators and BACE inhibitors reduce Aβ production without altering gene expression in Alzheimer's disease iPSC-derived neurons and mice. | Cusulin C et al. | — | 2019 | → |
| Heat Shock Factor 1 Is a Direct Antagonist of AMP-Activated Protein Kinase. | Su KH et al. | — | 2019 | → |
| High-throughput identification of factors promoting neuronal differentiation of human neural progenitor cells in microscale 3D cell culture. | Nierode GJ et al. | — | 2019 | → |
| Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development. | Karagiannis P et al. | — | 2019 | → |
| Induction of Autophagy and Activation of SIRT-1 Deacetylation Mechanisms Mediate Neuroprotection by the Pomegranate Metabolite Urolithin A in BV2 Microglia and Differentiated 3D Human Neural Progenitor Cells. | Velagapudi R et al. | — | 2019 | → |
| Induction of Neuroinflammation and Neurotoxicity by Synthetic Hemozoin. | Velagapudi R et al. | — | 2019 | → |
| Influence of Hydrophobic Cross-Linkers on Carboxybetaine Copolymer Stimuli Response and Hydrogel Biological Properties. | Huynh V et al. | — | 2019 | → |
| iPSCs-Based Neural 3D Systems: A Multidimensional Approach for Disease Modeling and Drug Discovery. | Costamagna G et al. | — | 2019 | → |
| Layer-By-Layer: The Case for 3D Bioprinting Neurons to Create Patient-Specific Epilepsy Models. | Antill-O'Brien N et al. | — | 2019 | → |
| Mechanisms of hyperexcitability in Alzheimer's disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. | Ghatak S et al. | — | 2019 | → |
| Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases. | Kumar S et al. | — | 2019 | → |
| Modeling Alzheimer's disease with human iPS cells: advancements, lessons, and applications. | Essayan-Perez S et al. | — | 2019 | → |
| Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids. | Kim H et al. | — | 2019 | → |
| Modelling mitochondrial dysfunction in Alzheimer's disease using human induced pluripotent stem cells. | Hawkins KE et al. | — | 2019 | → |
| Multi-site dynamic recording for Aβ oligomers-induced Alzheimer's disease in vitro based on neuronal network chip. | Gao F et al. | — | 2019 | → |
| Nanogroove-Enhanced Hydrogel Scaffolds for 3D Neuronal Cell Culture: An Easy Access Brain-on-Chip Model. | Bastiaens A et al. | — | 2019 | → |
| Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. | Vissers C et al. | — | 2019 | → |
| Neural Lineage Differentiation From Pluripotent Stem Cells to Mimic Human Brain Tissues. | Hong YJ et al. | — | 2019 | → |
| Neuro-regeneration Therapeutic for Alzheimer's Dementia: Perspectives on Neurotrophic Activity. | Sun MK et al. | — | 2019 | → |
| One Step Into the Future: New iPSC Tools to Advance Research in Parkinson's Disease and Neurological Disorders. | Mohamed NV et al. | — | 2019 | → |
| Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease. | Wu YY et al. | — | 2019 | → |
| Organotypic Brain Slices of ADULT Transgenic Mice: A Tool to Study Alzheimer's Disease. | Humpel C | — | 2019 | → |
| Overview of Transgenic Mouse Models for Alzheimer's Disease. | Myers A et al. | — | 2019 | → |
| Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs. | Nakamura M et al. | — | 2019 | → |
| rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies. | Croft CL et al. | — | 2019 | → |
| Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. | Taylor-Whiteley TR et al. | — | 2019 | → |
| Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease. | Dubey SK et al. | — | 2019 | → |
| Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. | Timmers M et al. | — | 2019 | → |
| Significant Upregulation of Alzheimer's β-Amyloid Levels in a Living System Induced by Extracellular Elastin Polypeptides. | Ma C et al. | — | 2019 | → |
| Spinal cord organoids add an extra dimension to traditional motor neuron cultures. | Winanto et al. | — | 2019 | → |
| Stem Cell-Derived Neurons as Cellular Models of Sporadic Alzheimer's Disease. | Foveau B et al. | — | 2019 | → |
| Structure-based inhibitors of amyloid beta core suggest a common interface with tau. | Griner SL et al. | — | 2019 | → |
| Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. | Logan S et al. | — | 2019 | → |
| Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects. | Dani M et al. | — | 2019 | → |
| Tau interactome analyses in CRISPR-Cas9 engineered neuronal cells reveal ATPase-dependent binding of wild-type but not P301L Tau to non-muscle myosins. | Wang X et al. | — | 2019 | → |
| The Astrocyte-Neuron Interface: An Overview on Molecular and Cellular Dynamics Controlling Formation and Maintenance of the Tripartite Synapse. | Hasan U et al. | — | 2019 | → |
| The complexity of tau in Alzheimer's disease. | Naseri NN et al. | — | 2019 | → |
| The First Generation of iPSC Line from a Korean Alzheimer's Disease Patient Carrying APP-V715M Mutation Exhibits a Distinct Mitochondrial Dysfunction. | Li L et al. | — | 2019 | → |
| The Use of Pluripotent Stem Cell-Derived Organoids to Study Extracellular Matrix Development during Neural Degeneration. | Yan Y et al. | — | 2019 | → |
| TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway. | Scotto Rosato A et al. | — | 2019 | → |
| Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. | Garcia-Leon JA et al. | — | 2019 | → |
| γ-Secretase and its modulators: Twenty years and beyond. | Xia W | — | 2019 | → |
| 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. | Centeno EGZ et al. | — | 2018 | → |
| 3D Culture Method for Alzheimer's Disease Modeling Reveals Interleukin-4 Rescues Aβ42-Induced Loss of Human Neural Stem Cell Plasticity. | Papadimitriou C et al. | — | 2018 | → |
| 3D human brain cell models: New frontiers in disease understanding and drug discovery for neurodegenerative diseases. | Korhonen P et al. | — | 2018 | → |
| 3D neural tissue models: From spheroids to bioprinting. | Zhuang P et al. | — | 2018 | → |
| 3D Printed Stem-Cell Derived Neural Progenitors Generate Spinal Cord Scaffolds. | Joung D et al. | — | 2018 | → |
| A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease. | Park J et al. | — | 2018 | → |
| Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. | Eimer WA et al. | — | 2018 | → |
| Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. | Li H et al. | — | 2018 | → |
| A new Alzheimer's disease cell model using B cells to induce beta amyloid plaque formation and increase TNF alpha expression. | Dezfulian M | — | 2018 | → |
| A New Fluorogenic Small-Molecule Labeling Tool for Surface Diffusion Analysis and Advanced Fluorescence Imaging of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Based on Silicone Rhodamine: SiR-BACE1. | Karch S et al. | — | 2018 | → |
| An integrated biomanufacturing platform for the large-scale expansion and neuronal differentiation of human pluripotent stem cell-derived neural progenitor cells. | Srinivasan G et al. | — | 2018 | → |
| A Novel Cell Penetrating Peptide for the Differentiation of Human Neural Stem Cells. | Ma W et al. | — | 2018 | → |
| A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-β oligomers. | Norambuena A et al. | — | 2018 | → |
| A report from the 8th Kuopio Alzheimer Symposium. | Haapasalo A et al. | — | 2018 | → |
| Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. | Condello C et al. | — | 2018 | → |
| Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons. | Engle SJ et al. | — | 2018 | → |
| Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. | Ma Q et al. | — | 2018 | → |
| Building Models of Brain Disorders with Three-Dimensional Organoids. | Amin ND et al. | — | 2018 | → |
| Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. | Dejanovic B et al. | — | 2018 | → |
| Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. | Cummings J et al. | — | 2018 | → |
| Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons. | Robbins JP et al. | — | 2018 | → |
| Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer's mouse model. | Choi SH et al. | — | 2018 | → |
| Common proteomic profiles of induced pluripotent stem cell-derived three-dimensional neurons and brain tissue from Alzheimer patients. | Chen M et al. | — | 2018 | → |
| Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. | Zhang C et al. | — | 2018 | → |
| CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. | Tabet R et al. | — | 2018 | → |
| Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease. | Kwak KA et al. | — | 2018 | → |
| Cytokine-mediated inflammation mediates painful neuropathy from metabolic syndrome. | Zhang C et al. | — | 2018 | → |
| Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. | Krell-Roesch J et al. | — | 2018 | → |
| Derivation of Cortical Spheroids from Human Induced Pluripotent Stem Cells in a Suspension Bioreactor. | Yan Y et al. | — | 2018 | → |
| Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review. | Lemche E | — | 2018 | → |
| Editorial: Prevention of Alzheimer's Disease in Chinese Populations: Status, Challenges and Directions. | Feng L et al. | — | 2018 | → |
| Effects of 3D culturing conditions on the transcriptomic profile of stem-cell-derived neurons. | Tekin H et al. | — | 2018 | → |
| Elucidating the Interactive Roles of Glia in Alzheimer's Disease Using Established and Newly Developed Experimental Models. | Chun H et al. | — | 2018 | → |
| Epigenetic alterations mediate iPSC-induced normalization of DNA repair gene expression and TNR stability in Huntington's disease cells. | Mollica PA et al. | — | 2018 | → |
| Exosome Theranostics: Biology and Translational Medicine. | He C et al. | — | 2018 | → |
| Functional and Sustainable 3D Human Neural Network Models from Pluripotent Stem Cells. | Cantley W et al. | — | 2018 | → |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | — | 2018 | → |
| Go with the Flow-Microfluidics Approaches for Amyloid Research. | Zilberzwige-Tal S et al. | — | 2018 | → |
| Human Neurospheroid Arrays for In Vitro Studies of Alzheimer's Disease. | Jorfi M et al. | — | 2018 | → |
| Hydrogel-incorporating unit in a well: 3D cell culture for high-throughput analysis. | Yu YJ et al. | — | 2018 | → |
| Intracellular tracing of amyloid vaccines through direct fluorescent labelling. | Mold M et al. | — | 2018 | → |
| In Vitro Microfluidic Models for Neurodegenerative Disorders. | Osaki T et al. | — | 2018 | → |
| iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia. | Li L et al. | — | 2018 | → |
| Is Alzheimer's Also a Stem Cell Disease? - The Zebrafish Perspective. | Kizil C et al. | — | 2018 | → |
| Is Parkinson's Disease a Neurodevelopmental Disorder and Will Brain Organoids Help Us to Understand It? | Schwamborn JC | — | 2018 | → |
| Lab-on-chip technology for chronic disease diagnosis. | Wu J et al. | — | 2018 | → |
| Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. | Cummings J | — | 2018 | → |
| Materials for Neural Differentiation, Trans-Differentiation, and Modeling of Neurological Disease. | Gong L et al. | — | 2018 | → |
| Mechanical stabilization of proteolytically degradable polyethylene glycol dimethacrylate hydrogels through peptide interaction. | Lim HJ et al. | — | 2018 | → |
| MiR-21 attenuates apoptosis-triggered by amyloid-β via modulating PDCD4/ PI3K/AKT/GSK-3β pathway in SH-SY5Y cells. | Feng MG et al. | — | 2018 | → |
| Modeling Alzheimer's disease brains in vitro. | Henstridge CM et al. | — | 2018 | → |
| Modeling amyloid beta and tau pathology in human cerebral organoids. | Gonzalez C et al. | — | 2018 | → |
| Modeling Late-Onset Sporadic Alzheimer's Disease through BMI1 Deficiency. | Flamier A et al. | — | 2018 | → |
| Modeling Neurodegenerative Microenvironment Using Cortical Organoids Derived from Human Stem Cells. | Yan Y et al. | — | 2018 | → |
| Modeling Neurological Diseases With Human Brain Organoids. | Wang H | — | 2018 | → |
| Modelling Alzheimer's disease: Insights from in vivo to in vitro three-dimensional culture platforms. | Ranjan VD et al. | — | 2018 | → |
| Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem Cells. | Rowland HA et al. | — | 2018 | → |
| Neuroprotective Activities of Heparin, Heparinase III, and Hyaluronic Acid on the A<i>β</i>42-Treated Forebrain Spheroids Derived from Human Stem Cells. | Bejoy J et al. | — | 2018 | → |
| Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains. | Guo L et al. | — | 2018 | → |
| Opportunities for organoids as new models of aging. | Hu JL et al. | — | 2018 | → |
| Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches. | Corrêa-Velloso JC et al. | — | 2018 | → |
| Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease. | Koh YH et al. | — | 2018 | → |
| Peptide Nanofiber Substrates for Long-Term Culturing of Primary Neurons. | Martin AD et al. | — | 2018 | → |
| Recent Advances: Decoding Alzheimer's Disease With Stem Cells. | Fang Y et al. | — | 2018 | → |
| Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity. | Bal-Price A et al. | — | 2018 | → |
| Representing Diversity in the Dish: Using Patient-Derived <i>in Vitro</i> Models to Recreate the Heterogeneity of Neurological Disease. | Ghaffari LT et al. | — | 2018 | → |
| Rodent models for Alzheimer disease. | Götz J et al. | — | 2018 | → |
| Role of cellular prion protein in interneuronal amyloid transmission. | Del Río JA et al. | — | 2018 | → |
| Rosmarinic Acid Derivatives' Inhibition of Glycogen Synthase Kinase-3β Is the Pharmacological Basis of Kangen-Karyu in Alzheimer's Disease. | Paudel P et al. | — | 2018 | → |
| Simple Synthetic Molecular Hydrogels from Self-Assembling Alkylgalactonamides as Scaffold for 3D Neuronal Cell Growth. | Chalard A et al. | — | 2018 | → |
| Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes. | Pavoni S et al. | — | 2018 | → |
| Somatic mutations in neurons during aging and neurodegeneration. | Verheijen BM et al. | — | 2018 | → |
| Stem cell models of human synapse development and degeneration. | Wilson ES et al. | — | 2018 | → |
| Stem Cells, Genome Editing, and the Path to Translational Medicine. | Soldner F et al. | — | 2018 | → |
| Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. | Castrillo JI et al. | — | 2018 | → |
| Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans. | Ikezu T et al. | — | 2018 | → |
| The antimicrobial protection hypothesis of Alzheimer's disease. | Moir RD et al. | — | 2018 | → |
| The Evolution of Polystyrene as a Cell Culture Material. | Lerman MJ et al. | — | 2018 | → |
| The rise of three-dimensional human brain cultures. | Pașca SP | — | 2018 | → |
| Three-Dimensional Models of the Human Brain Development and Diseases. | Jorfi M et al. | — | 2018 | → |
| Tissue Engineering 3D Neurovascular Units: A Biomaterials and Bioprinting Perspective. | Potjewyd G et al. | — | 2018 | → |
| Translational potential of human brain organoids. | Sun AX et al. | — | 2018 | → |
| Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact. | Moretti R et al. | — | 2018 | → |
| 3D brain Organoids derived from pluripotent stem cells: promising experimental models for brain development and neurodegenerative disorders. | Lee CT et al. | — | 2017 | → |
| Adapting tissue-engineered in vitro CNS models for high-throughput study of neurodegeneration. | O'Rourke C et al. | — | 2017 | → |
| A<i>β</i> Peptide Originated from Platelets Promises New Strategy in Anti-Alzheimer's Drug Development. | Inyushin MY et al. | — | 2017 | → |
| Alzheimer's disease: experimental models and reality. | Drummond E et al. | — | 2017 | → |
| Alzheimer's Disease: Insights from Genetic Mouse Models and Current Advances in Human IPSC-Derived Neurons. | Harasta AE et al. | — | 2017 | → |
| A Mouse Model of Alzheimer's Disease with Transplanted Stem-Cell-Derived Human Neurons. | Zhu Y et al. | — | 2017 | → |
| Amyloid β-Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143-Further Implications for Alzheimer's Therapy. | Chiarini A et al. | — | 2017 | → |
| An expandable embryonic stem cell-derived Purkinje neuron progenitor population that exhibits in vivo maturation in the adult mouse cerebellum. | Higuera GA et al. | — | 2017 | → |
| A Novel Three-Dimensional Culture System for Oligodendrocyte Precursor Cells. | Egawa N et al. | — | 2017 | → |
| Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APP<sub>SWE</sub>/PS1<sub>ΔE9</sub> murine model of Alzheimer's disease. | Minter MR et al. | — | 2017 | → |
| A Tissue Engineered Model of Aging: Interdependence and Cooperative Effects in Failing Tissues. | Acun A et al. | — | 2017 | → |
| Automated quantification of three-dimensional organization of fiber-like structures in biological tissues. | Liu Z et al. | — | 2017 | → |
| Back and forth in time: Directing age in iPSC-derived lineages. | Cornacchia D et al. | — | 2017 | → |
| Beyond mouse cancer models: Three-dimensional human-relevant in vitro and non-mammalian in vivo models for photodynamic therapy. | Kucinska M et al. | — | 2017 | → |
| Bioengineered 3D Glial Cell Culture Systems and Applications for Neurodegeneration and Neuroinflammation. | Watson PMD et al. | — | 2017 | → |
| Biological Basis for Amyloidogenesis in Alzheimer's Disease. | Andreeva TV et al. | — | 2017 | → |
| Cellular self-assembly and biomaterials-based organoid models of development and diseases. | Shah SB et al. | — | 2017 | → |
| Chromosome conformation and gene expression patterns differ profoundly in human fibroblasts grown in spheroids versus monolayers. | Chen H et al. | — | 2017 | → |
| Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. | Zuroff L et al. | — | 2017 | → |
| Comparison of 2D and 3D neural induction methods for the generation of neural progenitor cells from human induced pluripotent stem cells. | Chandrasekaran A et al. | — | 2017 | → |
| Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease. | Inak G et al. | — | 2017 | → |
| Defining Disease Modifying Therapy for Alzheimer's Disease. | Cummings J et al. | — | 2017 | → |
| Deriving, regenerating, and engineering CNS tissues using human pluripotent stem cells. | Lemke KA et al. | — | 2017 | → |
| Development and characterization of a human embryonic stem cell-derived 3D neural tissue model for neurotoxicity testing. | Sandström J et al. | — | 2017 | → |
| Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics. | Yilmaz A et al. | — | 2017 | → |
| Dickkopf 3 (Dkk3) Improves Amyloid-β Pathology, Cognitive Dysfunction, and Cerebral Glucose Metabolism in a Transgenic Mouse Model of Alzheimer's Disease. | Zhang L et al. | — | 2017 | → |
| Direct Conversion of Human Fibroblasts into Neural Progenitors Using Transcription Factors Enriched in Human ESC-Derived Neural Progenitors. | Hou PS et al. | — | 2017 | → |
| Dissociating Normal Aging from Alzheimer's Disease: A View from Cognitive Neuroscience. | Toepper M | — | 2017 | → |
| Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer's disease. | Wang Y et al. | — | 2017 | → |
| Endocytic uptake of monomeric amyloid-β peptides is clathrin- and dynamin-independent and results in selective accumulation of Aβ(1-42) compared to Aβ(1-40). | Wesén E et al. | — | 2017 | → |
| Fabrication of In Vitro Cancer Microtissue Array on Fibroblast-Layered Nanofibrous Membrane by Inkjet Printing. | Park TM et al. | — | 2017 | → |
| Fluorescent nanodiamond tracking reveals intraneuronal transport abnormalities induced by brain-disease-related genetic risk factors. | Haziza S et al. | — | 2017 | → |
| Functional Characterization of Resting and Adenovirus-Induced Reactive Astrocytes in Three-Dimensional Culture. | Woo J et al. | — | 2017 | → |
| Hallmarks of Alzheimer's Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain. | Espuny-Camacho I et al. | — | 2017 | → |
| Human astrocytes are distinct contributors to the complexity of synaptic function. | Krencik R et al. | — | 2017 | → |
| Human Induced Pluripotent Stem Cells and the Modelling of Alzheimer's Disease: The Human Brain Outside the Dish. | Tong G et al. | — | 2017 | → |
| Human induced pluripotent stem cells as a research tool in Alzheimer's disease. | Robbins JP et al. | — | 2017 | → |
| Human TAU<sup>P301L</sup> overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain. | Cosacak MI et al. | — | 2017 | → |
| Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease. | Sullivan SE et al. | — | 2017 | → |
| In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells. | Krishtal J et al. | — | 2017 | → |
| Interactions of pathological proteins in neurodegenerative diseases. | Spires-Jones TL et al. | — | 2017 | → |
| I-Wire Heart-on-a-Chip I: Three-dimensional cardiac tissue constructs for physiology and pharmacology. | Sidorov VY et al. | — | 2017 | → |
| LncRNAs: macromolecules with big roles in neurobiology and neurological diseases. | Chen Y et al. | — | 2017 | → |
| Mechanisms that synergistically regulate η-secretase processing of APP and Aη-α protein levels: relevance to pathogenesis and treatment of Alzheimer's disease. | Ward J et al. | — | 2017 | → |
| Microglia emerge as central players in brain disease. | Salter MW et al. | — | 2017 | → |
| Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges. | Poon A et al. | — | 2017 | → |
| Modeling tau pathology in human stem cell derived neurons. | Wray S | — | 2017 | → |
| Modelling APOE ɛ3/4 allele-associated sporadic Alzheimer's disease in an induced neuron. | Kim H et al. | — | 2017 | → |
| Monitoring and manipulating cellular crosstalk during kidney fibrosis inside a 3D in vitro co-culture. | Nugraha B et al. | — | 2017 | → |
| Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. | Rabinovici GD et al. | — | 2017 | → |
| Nanoplasmonic fiber tip probe detects significant reduction of intracellular Alzheimer's disease-related oligomers by curcumin. | Liang F et al. | — | 2017 | → |
| Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease. | Faustino C et al. | — | 2017 | → |
| Neurophysiological Changes Induced by Chronic Toxoplasma gondii Infection. | Tedford E et al. | — | 2017 | → |
| Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. | Reilly P et al. | — | 2017 | → |
| Overexpression of let-7a increases neurotoxicity in a PC12 cell model of Alzheimer's disease via regulating autophagy. | Gu H et al. | — | 2017 | → |
| Paving the Way Toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells. | Lauschke K et al. | — | 2017 | → |
| Pharmacological and Toxicological Properties of the Potent Oral <i>γ</i>-Secretase Modulator BPN-15606. | Wagner SL et al. | — | 2017 | → |
| Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition. | Berman MH et al. | — | 2017 | → |
| Polymeric scaffolds for three-dimensional culture of nerve cells: a model of peripheral nerve regeneration. | Ayala-Caminero R et al. | — | 2017 | → |
| PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. | Oksanen M et al. | — | 2017 | → |
| Recent Progress in Alzheimer's Disease Research, Part 1: Pathology. | Hane FT et al. | — | 2017 | → |
| Reprogramming cells from Gulf War veterans into neurons to study Gulf War illness. | Qiang L et al. | — | 2017 | → |
| Scaffolds for 3D in vitro culture of neural lineage cells. | Murphy AR et al. | — | 2017 | → |
| Simplified Murine 3D Neuronal Cultures for Investigating Neuronal Activity and Neurodegeneration. | Collins SJ et al. | — | 2017 | → |
| Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease. | Bukhari H et al. | — | 2017 | → |
| Soft Hydrogels Featuring In-Depth Surface Density Gradients for the Simple Establishment of 3D Tissue Models for Screening Applications. | Zhang N et al. | — | 2017 | → |
| Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1. | Raven F et al. | — | 2017 | → |
| Stem cell models of Alzheimer's disease: progress and challenges. | Arber C et al. | — | 2017 | → |
| Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony. | Forner S et al. | — | 2017 | → |
| Tau-based therapies in neurodegeneration: opportunities and challenges. | Li C et al. | — | 2017 | → |
| Testing the Amyloid Hypothesis with a Humanized AD Mouse Model. | Cahill MK et al. | — | 2017 | → |
| The Emerging Role of Innate Immunity in Alzheimer's Disease. | Vijaya Kumar DK et al. | — | 2017 | → |
| The Exceptional Vulnerability of Humans to Alzheimer's Disease. | Walker LC et al. | — | 2017 | → |
| The Future in Disease Models for Mass Spectrometry Imaging, Ethical Issues, and the Way Forward. | Day RE et al. | — | 2017 | → |
| The use of brain organoids to investigate neural development and disease. | Di Lullo E et al. | — | 2017 | → |
| Three-dimensional tissues using human pluripotent stem cell spheroids as biofabrication building blocks. | Lin H et al. | — | 2017 | → |
| Toward modeling the human nervous system in a dish: recent progress and outstanding challenges. | Vagaska B et al. | — | 2017 | → |
| Understanding Alzheimer's disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: A chance for new biomarkers in neuroproteomics? | Lassen PS et al. | — | 2017 | → |
| Using induced pluripotent stem cells to explore genetic and epigenetic variation associated with Alzheimer's disease. | Imm J et al. | — | 2017 | → |
| 3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish". | Choi SH et al. | — | 2016 | → |
| Accelerating stem cell trials for Alzheimer's disease. | Hunsberger JG et al. | — | 2016 | → |
| A decade of progress in tissue engineering. | Khademhosseini A et al. | — | 2016 | → |
| Advances in Stem Cell Research- A Ray of Hope in Better Diagnosis and Prognosis in Neurodegenerative Diseases. | Singh S et al. | — | 2016 | → |
| Advancing multiscale structural mapping of the brain through fluorescence imaging and analysis across length scales. | Hogstrom LJ et al. | — | 2016 | → |
| Alzheimer's disease. | Scheltens P et al. | — | 2016 | → |
| Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. | Sala Frigerio C et al. | — | 2016 | → |
| Alzheimer's disease: the amyloid hypothesis on trial. | Harrison JR et al. | — | 2016 | → |
| Alzheimer's disease via enhanced calcium signaling caused by the decrease of endoplasmic reticulum-mitochondrial distance. | Qi H et al. | — | 2016 | → |
| Analytic Models of Oxygen and Nutrient Diffusion, Metabolism Dynamics, and Architecture Optimization in Three-Dimensional Tissue Constructs with Applications and Insights in Cerebral Organoids. | McMurtrey RJ | — | 2016 | → |
| Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. | Minter MR et al. | — | 2016 | → |
| Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence. | Yamazaki Y et al. | — | 2016 | → |
| Automated longitudinal monitoring of in vivo protein aggregation in neurodegenerative disease C. elegans models. | Cornaglia M et al. | — | 2016 | → |
| Benefits of Strategic Small-Scale Targeted Screening. | Sharlow ER | — | 2016 | → |
| Bioengineered cell culture systems of central nervous system injury and disease. | Teixeira FG et al. | — | 2016 | → |
| Bio-inspired 3D microenvironments: a new dimension in tissue engineering. | Magin CM et al. | — | 2016 | → |
| Biomimetic on-a-chip platforms for studying cancer metastasis. | Lee E et al. | — | 2016 | → |
| Bioprinting towards Physiologically Relevant Tissue Models for Pharmaceutics. | Peng W et al. | — | 2016 | → |
| Brain Aggregates: An Effective In Vitro Cell Culture System Modeling Neurodegenerative Diseases. | Ahn M et al. | — | 2016 | → |
| Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease. | Chiarini A et al. | — | 2016 | → |
| Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases. | Haston KM et al. | — | 2016 | → |
| CNS disease models with human pluripotent stem cells in the CRISPR age. | Muffat J et al. | — | 2016 | → |
| Conversion of Synthetic Aβ to In Vivo Active Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model. | Novotny R et al. | — | 2016 | → |
| Creation of a library of induced pluripotent stem cells from Parkinsonian patients. | Holmqvist S et al. | — | 2016 | → |
| Development of a Scalable, High-Throughput-Compatible Assay to Detect Tau Aggregates Using iPSC-Derived Cortical Neurons Maintained in a Three-Dimensional Culture Format. | Medda X et al. | — | 2016 | → |
| Differentiation Induction of Mouse Neural Stem Cells in Hydrogel Tubular Microenvironments with Controlled Tube Dimensions. | Onoe H et al. | — | 2016 | → |
| Direct High Affinity Interaction between Aβ42 and GSK3α Stimulates Hyperphosphorylation of Tau. A New Molecular Link in Alzheimer's Disease? | Dunning CJ et al. | — | 2016 | → |
| Direct Tracking of Amyloid and Tu Dynamics in Neuroblastoma Cells Using Nanoplasmonic Fiber Tip Probes. | Liang F et al. | — | 2016 | → |
| Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells. | Watmuff B et al. | — | 2016 | → |
| Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. | Talwar P et al. | — | 2016 | → |
| Drug development in Alzheimer's disease: the path to 2025. | Cummings J et al. | — | 2016 | → |
| Effective motor neuron differentiation of hiPSCs on a patch made of crosslinked monolayer gelatin nanofibers. | Tang Y et al. | — | 2016 | → |
| Efficient synthesis of longer Aβ peptides via removable backbone modification. | Zuo C et al. | — | 2016 | → |
| Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases. | Irwin MH et al. | — | 2016 | → |
| Expandable and Rapidly Differentiating Human Induced Neural Stem Cell Lines for Multiple Tissue Engineering Applications. | Cairns DM et al. | — | 2016 | → |
| Expectations for the methodology and translation of animal research: a survey of the general public, medical students and animal researchers in North America. | Joffe AR et al. | — | 2016 | → |
| Functional metabolic interactions of human neuron-astrocyte 3D in vitro networks. | Simão D et al. | — | 2016 | → |
| Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. | Vasconcelos B et al. | — | 2016 | → |
| High-throughput platforms for the screening of new therapeutic targets for neurodegenerative diseases. | Rocha DN et al. | — | 2016 | → |
| High-Throughput Toxicity and Phenotypic Screening of 3D Human Neural Progenitor Cell Cultures on a Microarray Chip Platform. | Nierode GJ et al. | — | 2016 | → |
| Human Neural Tissue Construct Fabrication Based on Scaffold-Free Tissue Engineering. | Takahashi H et al. | — | 2016 | → |
| Immunization with Small Amyloid-β-derived Cyclopeptide Conjugates Diminishes Amyloid-β-Induced Neurodegeneration in Mice. | Mulder CK et al. | — | 2016 | → |
| Induced pluripotent stem cells in Alzheimer's disease: applications for disease modeling and cell-replacement therapy. | Yang J et al. | — | 2016 | → |
| Ion channel regulation by β-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease. | Lehnert S et al. | — | 2016 | → |
| iPS Cells-The Triumphs and Tribulations. | Sharma R | — | 2016 | → |
| Layered hydrogels accelerate iPSC-derived neuronal maturation and reveal migration defects caused by MeCP2 dysfunction. | Zhang ZN et al. | — | 2016 | → |
| Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data. | Guhra M et al. | — | 2016 | → |
| Live imaging of microtubule dynamics in organotypic hippocampal slice cultures. | Schätzle P et al. | — | 2016 | → |
| LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease. | Pinnock EC et al. | — | 2016 | → |
| Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells. | Mungenast AE et al. | — | 2016 | → |
| Modeling Alzheimer's Disease with Induced Pluripotent Stem Cells: Current Challenges and Future Concerns. | Zhang W et al. | — | 2016 | → |
| Moving from the Dish to the Clinical Practice: A Decade of Lessons and Perspectives from the Pre-Clinical and Clinical Stem Cell Studies for Alzheimer's Disease. | Salem H et al. | — | 2016 | → |
| Multi-compartmental biomaterial scaffolds for patterning neural tissue organoids in models of neurodevelopment and tissue regeneration. | McMurtrey RJ | — | 2016 | → |
| Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets. | Grubman A et al. | — | 2016 | → |
| Nanoengineering neural stem cells on biomimetic substrates using magnetofection technology. | Adams CF et al. | — | 2016 | → |
| Neural patterning of human induced pluripotent stem cells in 3-D cultures for studying biomolecule-directed differential cellular responses. | Yan Y et al. | — | 2016 | → |
| Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease. | Snow WM et al. | — | 2016 | → |
| Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. | Tang S et al. | — | 2016 | → |
| Polymer Thin Films with Tunable Acetylcholine-like Functionality Enable Long-Term Culture of Primary Hippocampal Neurons. | Yu SB et al. | — | 2016 | → |
| Rab-mediated membrane trafficking and the control of epithelial cell polarity. | Ioannou MS et al. | — | 2016 | → |
| Revisiting rodent models: Octodon degus as Alzheimer's disease model? | Steffen J et al. | — | 2016 | → |
| Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes. | Raja WK et al. | — | 2016 | → |
| Tau neurotoxicity and rescue in animal models of human Tauopathies. | Krüger L et al. | — | 2016 | → |
| The amyloid hypothesis of Alzheimer's disease at 25 years. | Selkoe DJ et al. | — | 2016 | → |
| The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model. | Li T et al. | — | 2016 | → |
| The positional identity of iPSC-derived neural progenitor cells along the anterior-posterior axis is controlled in a dosage-dependent manner by bFGF and EGF. | Zhou S et al. | — | 2016 | → |
| The use of human neurons for novel drug discovery in dementia research. | Vargas-Caballero M et al. | — | 2016 | → |
| Three Dimensional Human Neuro-Spheroid Model of Alzheimer's Disease Based on Differentiated Induced Pluripotent Stem Cells. | Lee HK et al. | — | 2016 | → |
| Translating the Science of Aging into Therapeutic Interventions. | Kirkland JL | — | 2016 | → |
| Utilizing stem cells for three-dimensional neural tissue engineering. | Knowlton S et al. | — | 2016 | → |
| Walking the tightrope: proteostasis and neurodegenerative disease. | Yerbury JJ et al. | — | 2016 | → |
| A 3D human neural cell culture system for modeling Alzheimer's disease. | Kim YH et al. | — | 2015 | → |
| Access to Clinical Therapeutics. | Shader RI | — | 2015 | → |
| Advances in reprogramming-based study of neurologic disorders. | Nityanandam A et al. | — | 2015 | → |
| A Human-Based Integrated Framework for Alzheimer's Disease Research. | Pistollato F et al. | — | 2015 | → |
| Alzheimer's disease and other dementias: advances in 2014. | Bateman R | — | 2015 | → |
| Alzheimer's in 3D culture: challenges and perspectives. | D'Avanzo C et al. | — | 2015 | → |
| APP metabolism regulates tau proteostasis in human cerebral cortex neurons. | Moore S et al. | — | 2015 | → |
| Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function. | Barucker C et al. | — | 2015 | → |
| A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. | Weissmiller AM et al. | — | 2015 | → |
| Being human: The role of pluripotent stem cells in regenerative medicine and humanizing Alzheimer's disease models. | Sproul AA | — | 2015 | → |
| Calcium sensing receptor mediated the excessive generation of β-amyloid peptide induced by hypoxia in vivo and in vitro. | Bai S et al. | — | 2015 | → |
| Cell Sheet-Based Tissue Engineering for Organizing Anisotropic Tissue Constructs Produced Using Microfabricated Thermoresponsive Substrates. | Takahashi H et al. | — | 2015 | → |
| Clinical strategies and animal models for developing senolytic agents. | Kirkland JL et al. | — | 2015 | → |
| Developing predictive assays: the phenotypic screening "rule of 3". | Vincent F et al. | — | 2015 | → |
| Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. | Sposito T et al. | — | 2015 | → |
| Dimeric bis (heptyl)-Cognitin Blocks Alzheimer's β-Amyloid Neurotoxicity Via the Inhibition of Aβ Fibrils Formation and Disaggregation of Preformed Fibrils. | Hu SQ et al. | — | 2015 | → |
| Does the difference between PART and Alzheimer's disease lie in the age-related changes in cerebral arteries that trigger the accumulation of Aβ and propagation of tau? | Weller RO et al. | — | 2015 | → |
| Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening? | Eglen RM et al. | — | 2015 | → |
| Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. | Kim TW | — | 2015 | → |
| Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β. | Amin J et al. | — | 2015 | → |
| Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics. | Zhao L et al. | — | 2015 | → |
| Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. | Saykin AJ et al. | — | 2015 | → |
| Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System. | Hunsberger JG et al. | — | 2015 | → |
| Inhibition of protein aggregation and amyloid formation by small molecules. | Doig AJ et al. | — | 2015 | → |
| Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System. | Shyam R et al. | — | 2015 | → |
| In vitro bioengineered model of cortical brain tissue. | Chwalek K et al. | — | 2015 | → |
| Ionizing radiation-induced adaptive response in fibroblasts under both monolayer and 3-dimensional conditions. | Zhao Y et al. | — | 2015 | → |
| Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. | Millan MJ et al. | — | 2015 | → |
| Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research. | Langley G et al. | — | 2015 | → |
| Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment. | Kemppainen N et al. | — | 2015 | → |
| Massachusetts Alzheimer's Disease Research Center: progress and challenges. | Hyman BT et al. | — | 2015 | → |
| Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. | Trevisan M et al. | — | 2015 | → |
| Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. | Crespi GA et al. | — | 2015 | → |
| Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease. | Lloret A et al. | — | 2015 | → |
| Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. | Zhang X et al. | — | 2015 | → |
| NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. | Goedert M | — | 2015 | → |
| Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro. | Bardy C et al. | — | 2015 | → |
| Novel advancements in three-dimensional neural tissue engineering and regenerative medicine. | McMurtrey RJ | — | 2015 | → |
| Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease. | Jovanovic K et al. | — | 2015 | → |
| On human pluripotent stem cell control: The rise of 3D bioengineering and mechanobiology. | Shao Y et al. | — | 2015 | → |
| Organotypic brain slice cultures: A review. | Humpel C | — | 2015 | → |
| Preventing Alzheimer's disease by means of natural selection. | Demetrius LA et al. | — | 2015 | → |
| Probing disorders of the nervous system using reprogramming approaches. | Ichida JK et al. | — | 2015 | → |
| Probing the secrets of Alzheimer's disease using human-induced pluripotent stem cell technology. | Goldstein LS et al. | — | 2015 | → |
| Progression of Seed-Induced Aβ Deposition within the Limbic Connectome. | Ye L et al. | — | 2015 | → |
| Propagation of prions causing synucleinopathies in cultured cells. | Woerman AL et al. | — | 2015 | → |
| Recapitulating amyloid β and tau pathology in human neural cell culture models: clinical implications. | Choi SH et al. | — | 2015 | → |
| Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease. | Macauley SL et al. | — | 2015 | → |
| Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease. | Caccamo A et al. | — | 2015 | → |
| Seeking the right context for evaluating nanomedicine: from tissue models in petri dishes to microfluidic organs-on-a-chip. | Zhang YS et al. | — | 2015 | → |
| Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. | Ferreira ST et al. | — | 2015 | → |
| Systems biology of neurodegenerative diseases. | Wood LB et al. | — | 2015 | → |
| The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases. | Baron BW et al. | — | 2015 | → |
| The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease. | MacLeod R et al. | — | 2015 | → |
| Three-Dimensional Neural Spheroid Culture: An In Vitro Model for Cortical Studies. | Dingle YT et al. | — | 2015 | → |
| Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. | Musiek ES et al. | — | 2015 | → |
| Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. | Braun RJ | — | 2015 | → |
| Using Human iPSC-Derived Neurons to Model TAU Aggregation. | Verheyen A et al. | — | 2015 | → |
| Vitamin D and Alzheimer's Disease: Neurocognition to Therapeutics. | Banerjee A et al. | — | 2015 | → |
| γ-Secretase modulators reduce endogenous amyloid β42 levels in human neural progenitor cells without altering neuronal differentiation. | D'Avanzo C et al. | — | 2015 | → |
| Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. | Stancu IC et al. | — | 2014 | → |
| Neurodegenerative disease: New dimensions in Alzheimer's modelling. | Whalley K | — | 2014 | → |
| New tools for the evaluation of patients with neurodegenerative diseases. | Dickerson BC | — | 2014 | → |
| Opportunities and Limitations of Modelling Alzheimer's Disease with Induced Pluripotent Stem Cells. | Ovchinnikov DA et al. | — | 2014 | → |
| The evolution of preclinical Alzheimer's disease: implications for prevention trials. | Sperling R et al. | — | 2014 | → |